<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Mol Life Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cell. Mol. Life Sci</journal-id><journal-title-group><journal-title>Cellular and Molecular Life Sciences</journal-title></journal-title-group><issn pub-type="ppub">1420-682X</issn><issn pub-type="epub">1420-9071</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7079810</article-id><article-id pub-id-type="pmid">31172218</article-id><article-id pub-id-type="publisher-id">3174</article-id><article-id pub-id-type="doi">10.1007/s00018-019-03174-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>MMPs and ADAMs in neurological infectious diseases and multiple sclerosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Muri</surname><given-names>Lukas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Leppert</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Grandgirard</surname><given-names>Denis</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1106-6123</contrib-id><name><surname>Leib</surname><given-names>Stephen L.</given-names></name><address><phone>+41 31 632 49 49</phone><email>stephen.leib@ifik.unibe.ch</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0726 5157</institution-id><institution-id institution-id-type="GRID">grid.5734.5</institution-id><institution>Neuroinfection Laboratory, Institute for Infectious Diseases, </institution><institution>University of Bern, </institution></institution-wrap>Friedb&#x000fc;hlstrasse 51, 3001 Bern, Switzerland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0726 5157</institution-id><institution-id institution-id-type="GRID">grid.5734.5</institution-id><institution>Graduate School for Cellular and Biomedical Sciences (GCB), </institution><institution>University of Bern, </institution></institution-wrap>Freiestrasse 1, 3012 Bern, Switzerland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.410567.1</institution-id><institution>Department of Neurology, </institution><institution>University Hospital Basel, </institution></institution-wrap>Petersgraben 4, 4031 Basel, Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="ppub"><year>2019</year></pub-date><volume>76</volume><issue>16</issue><fpage>3097</fpage><lpage>3116</lpage><history><date date-type="received"><day>23</day><month>5</month><year>2019</year></date><date date-type="rev-recd"><day>23</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>29</day><month>5</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; Springer Nature Switzerland AG 2019</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Metalloproteinases&#x02014;such as matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinases (ADAMs)&#x02014;are involved in various diseases of the nervous system but also contribute to nervous system development, synaptic plasticity and neuroregeneration upon injury. MMPs and ADAMs proteolytically cleave many substrates including extracellular matrix components but also signaling molecules and receptors. During neuroinfectious disease with associated neuroinflammation, MMPs and ADAMs regulate blood&#x02013;brain barrier breakdown, bacterial invasion, neutrophil infiltration and cytokine signaling. Specific and broad-spectrum inhibitors for MMPs and ADAMs have experimentally been shown to decrease neuroinflammation and brain damage in diseases with excessive neuroinflammation as a common denominator, such as pneumococcal meningitis and multiple sclerosis, thereby improving the disease outcome. Timing of metalloproteinase inhibition appears to be critical to effectively target the cascade of pathophysiological processes leading to brain damage without inhibiting the neuroregenerative effects of metalloproteinases. As the critical role of metalloproteinases in neuronal repair mechanisms and regeneration was only lately recognized, the original idea of chronic MMP inhibition needs to be conceptually revised. Recently accumulated research urges for a second chance of metalloproteinase inhibitors, which&#x02014;when correctly applied and dosed&#x02014;harbor the potential to improve the outcome of different neuroinflammatory diseases.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Neuroinfection</kwd><kwd>Neuroinflammation</kwd><kwd>Bacterial meningitis</kwd><kwd>Metalloproteinase</kwd><kwd>MMP</kwd><kwd>Multiple sclerosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Switzerland AG 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>MMPs and ADAMs and their function in the CNS</title><p id="Par27">Matrix metalloproteinases (MMPs) and A disintegrin and metalloproteinases (ADAMs) belong to the class of metzincin metalloproteinases containing a conserved Met residue at their active site and using a zinc ion during the enzymatic reaction. These metalloproteinases are involved in many neurological conditions but also contribute crucially to neurophysiological functions, such as synaptic plasticity and neuroregeneration via regulating stem cell biology and remyelination [<xref ref-type="bibr" rid="CR1">1</xref>]. Until now, 24 different mammalian MMPs are described, while each type has a defined substrate specificity [<xref ref-type="bibr" rid="CR2">2</xref>]. Collectively, MMPs can degrade all components of the extracellular matrix (ECM) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Apart from degrading ECM, MMPs are also able to cleave adhesion molecules, receptors and growth factors [<xref ref-type="bibr" rid="CR4">4</xref>], indicating an involvement of MMPs in cell migration, signaling, differentiation, cell survival or apoptosis, angiogenesis and inflammation [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. ADAMs also have the capacity to degrade and remodel components of the ECM, but their best characterized function is protein ectodomain shedding, thereby processing and releasing mature proteins (e.g., TNF-&#x003b1;) from membrane-anchored precursors [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. During pathological conditions of the central nervous system (CNS), metalloproteinases derive from infiltrating leukocytes (neutrophils, macrophages and lymphocytes) or brain-resident cells (microglia, astrocytes and neurons) [<xref ref-type="bibr" rid="CR7">7</xref>].</p><sec id="Sec2"><title>Regulation of metalloproteinase activity</title><p id="Par28">As metalloproteinases have the capacity for extensive tissue destruction, their activity is tightly regulated and controlled [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The catalytic activity of MMPs is regulated on four different levels; namely gene expression, compartmentalization, pro-enzyme activation and enzyme inhibition [<xref ref-type="bibr" rid="CR5">5</xref>]. Pro-MMPs are kept in a catalytically inactive state and can be activated by proteolytic cleavage of the pro-domain or by modification of the pro-domain&#x02019;s cysteine thiol group [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Of importance for inflammatory and infectious processes, reactive oxygen species (ROS) have the potential to activate MMPs via oxidation of the pro-domain&#x02019;s thiol group [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. MMP inactivation might be achieved be natural inhibitors, of which the tissue inhibitors of metalloproteinases (TIMPs) are the most prominent ones. By binding to the catalytic site of MMPs, the four TIMPs (TIMP-1, -2, -3 and -4) are able to terminate MMP activity [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Many TIMPs target multiple metalloproteinases, but there are also some strict specificities such as TIMP-3, which is the only TIMP to inhibit ADAM17 [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p></sec></sec><sec id="Sec3"><title>Effect of metalloproteinases on BBB integrity</title><p id="Par29">The contribution of MMPs on blood&#x02013;brain barrier (BBB) integrity was demonstrated for the first time in the early 1990s by inducing BBB breakdown after intracerebroventricular administration of MMP-2 and MMP-9, an effect that was prevented by simultaneous administration of TIMP-2 [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. Subsequent findings of elevated MMP-9 levels after cerebral insults for the first time established a link between MMPs and inflammation in the CNS [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Intracerebral injection of lipopolysaccharide (LPS)&#x02014;mimicking bacterial brain infections&#x02014;increased MMP-2, MMP-3 and TNF-&#x003b1; mRNA levels [<xref ref-type="bibr" rid="CR20">20</xref>] and induced BBB disruption through the action of MMP-9 [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par30">Blood&#x02013;brain barrier opening is associated with a morphological redistribution of tight junction (TJ) and adherens junction (AJ) proteins from the membrane to the cytoplasm [<xref ref-type="bibr" rid="CR22">22</xref>]. In different neurological pathologies, MMPs are reported to degrade TJ and basal lamina proteins, thereby inducing BBB leakage with subsequent neutrophil infiltration, brain edema and hemorrhage [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par31">The role of MMP-2 in BBB opening was intensively studied in cerebral ischemia models, where MMP-2 was found to play an important role in the initial BBB opening [<xref ref-type="bibr" rid="CR24">24</xref>] with increased activation of MMP-2 being associated with the degradation of the TJ proteins claudin-5 and occludin [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Both MMP-2 and MMP-9 (gelatinase A and B) are able to degrade the major components of the basal lamina (type IV collagen, laminin and fibronectin) surrounding the cerebral blood vessels, thus increasing BBB permeability [<xref ref-type="bibr" rid="CR22">22</xref>]. In vitro and in vivo, MMP-9 is capable of degrade claudin-5, occludin and ZO-1, thereby participating in TJ degradation [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Experimental data propose that MMP-9&#x02014;which plays a profound role in delayed BBB breakdown [<xref ref-type="bibr" rid="CR28">28</xref>]&#x02014;derives mostly from brain microvascular endothelial cells and infiltrating neutrophils [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. Infiltrating neutrophils contain stores of MMP-9&#x02014;so-called tertiary granules (or gelatinase granules)&#x02014;which are rapidly released upon entering the site of injury [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. MMP-9 levels critically increase during bacterial meningitis and elevated MMP-9 levels are associated with BBB damage and neurological sequelae [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. In experimental ischemic stroke, increased neutrophil-derived MMP-9 is critically involved in a state of systemic inflammation with sustained degradation of TJ and basal lamina proteins leading to exacerbated brain injury [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Apart from these two gelatinases, other MMPs influence BBB integrity. MMP-3 is able to degrade laminin, gelatin, E-cadherin, proteoglycans and fibronectin [<xref ref-type="bibr" rid="CR36">36</xref>] and has been demonstrated to mediate BBB opening after LPS-induced neuroinflammation, thereby facilitating neutrophil infiltration [<xref ref-type="bibr" rid="CR37">37</xref>]. Collagenases (MMP-1, -8 and -13) preferentially cleave helical collagens in the ECM [<xref ref-type="bibr" rid="CR22">22</xref>] and are reported to be activated and/or upregulated in vessels with BBB impairment [<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. In bacterial meningitis, cerebrospinal fluid (CSF) levels of MMP-13 and MMP-8 are upregulated [<xref ref-type="bibr" rid="CR41">41</xref>] and associated with BBB damage [<xref ref-type="bibr" rid="CR35">35</xref>]. Repeated lumbar punctures in bacterial meningitis patients revealed that MMP-8 levels were regulated independently and did not correlate with CSF granulocyte cell counts, indicating that these MMPs might not only be secreted by infiltrating neutrophils but also from brain-resident cells [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par32">Neural vascular barrier function is also regulated by ADAMs. ADAM12 and ADAM17 were shown to control neural vascular barrier function upon hypoxic stimuli by diminishing claudin-5 in brain microvascular endothelial cells, an effect that was prevented by specific inhibition of ADAM12 or ADAM17 [<xref ref-type="bibr" rid="CR42">42</xref>]. Activated ADAM10 cleaves VE-cadherin and promotes leukocyte migration to inter-endothelial junctions [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p></sec><sec id="Sec4"><title>MMPs and ADAMs in progression of neuroinflammation</title><p id="Par33">As the first described MMP was found to degrade collagen [<xref ref-type="bibr" rid="CR45">45</xref>], the following contributions on MMPs mostly focused on their ability to degrade ECM components [<xref ref-type="bibr" rid="CR5">5</xref>]. More recent data suggest, however, that MMPs have a much wider range of activity, including non-matrix substrates [<xref ref-type="bibr" rid="CR4">4</xref>]. Instead of clustering MMPs together for their function in ECM degradation, Parks et al. suggest to categorize them rather according to their role in inflammation [<xref ref-type="bibr" rid="CR5">5</xref>]. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> summarize functions of selected metalloproteinases in pro- and anti-inflammatory processes.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Metalloproteinase and their regulatory function in neuroinflammation.&#x000a0;MMPs are important regulators of inflammation by controlling cytokine activity and chemotactic gradients, thereby manipulating leukocyte migration. This table contains selected and intensively studied metalloproteinases with their substrate specificity (excluding their classical substrates in ECM degradation) and their involvement in BBB breakdown and inflammation. Special attention should be paid to the concept of metalloproteinase involvement in inflammation termination (e.g., CCL7 cleavage of MMP-2 or CXCL5, 6, 12 inactivation by MMP-9) and induction of repair processes (TGF-&#x003b2; activation by MMP-3 and -14 or EGFR signaling by ADAM10 and 17)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Metallo-proteinase</th><th align="left">Common name</th><th align="left">Substrate</th><th align="left">Biological function during inflammation</th><th align="left">References</th></tr></thead><tbody><tr><td align="left" rowspan="2">MMP-1</td><td align="left" rowspan="2">Collagenase-1</td><td align="left">CCL7, MCP-1,-2,-4</td><td align="left">Regulation of chemokine signaling</td><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td align="left">CXCL12 (SDF-1&#x003b1;)</td><td align="left"/><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left" rowspan="5">MMP-2</td><td align="left" rowspan="5">Gelatinase A</td><td align="left">CCL7 (MCP3)</td><td align="left">Regulation of chemokine signaling</td><td align="left">[<xref ref-type="bibr" rid="CR47">47</xref>]</td></tr><tr><td align="left">CXCL12 (SDF-1&#x003b1;)</td><td align="left">Chemotactic gradient</td><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left">(CCL11 gradient)</td><td align="left"/><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left">pIL-1&#x003b2;</td><td align="left">IL-1&#x003b2; activation</td><td align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left">Claudin-5, occludin</td><td align="left">Junction protein degradation</td><td align="left">[<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr><td align="left" rowspan="5">MMP-3</td><td align="left" rowspan="5">Stromelysin-1</td><td align="left">CCL7, MCP-1,-2,-4</td><td align="left">Regulation of chemokine signaling</td><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td align="left">CXCL12 (SDF-1&#x003b1;)</td><td align="left"/><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left">pIL-1&#x003b2;</td><td align="left">IL-1&#x003b2; activation</td><td align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left">Latent TGF-&#x003b2;1</td><td align="left">Pot. anti-inflammatory response</td><td align="left">[<xref ref-type="bibr" rid="CR68">68</xref>]</td></tr><tr><td align="left">E-cadherin</td><td align="left">Junction protein degradation</td><td align="left">[<xref ref-type="bibr" rid="CR36">36</xref>]</td></tr><tr><td align="left" rowspan="2">MMP-7</td><td align="left" rowspan="2">Matrilysin</td><td align="left">Syndecan-1 (CXCL1 release)</td><td align="left">Chemotactic gradient</td><td align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left">proTNF&#x003b1;</td><td align="left">TNF-&#x003b1; activation</td><td align="left">[<xref ref-type="bibr" rid="CR65">65</xref>]</td></tr><tr><td align="left" rowspan="3">MMP-8</td><td align="left" rowspan="3">Collagenase-2</td><td align="left">LIX</td><td align="left">Chemotactic gradient</td><td align="left">[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td align="left">CXCL6, CXCL5, LIX</td><td align="left">Regulation of chemokine signaling</td><td align="left">[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left">Occludin</td><td align="left">Junction protein degradation</td><td align="left">[<xref ref-type="bibr" rid="CR131">131</xref>]</td></tr><tr><td align="left" rowspan="7">MMP-9</td><td align="left" rowspan="7">Gelatinase B</td><td align="left">CXCL8 (IL-8)</td><td align="left">Chemotactic gradient</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left">CXCL12 (SDF-1&#x003b1;)</td><td align="left">Regulation of chemokine signaling</td><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left">CXCL6, CXCL5, LIX</td><td align="left"/><td align="left">[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left">(CCL11, CCL7, CCL17 gradient)</td><td align="left"/><td align="left">[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left">pIL-1&#x003b2;</td><td align="left">IL-1&#x003b2; activation</td><td align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left">Latent TGF-&#x003b2;1</td><td align="left">Pot. anti-inflammatory response</td><td align="left">[<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr><tr><td align="left">Claudin-5, occludin, ZO-1</td><td align="left">Junction protein degradation</td><td align="left">[<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr><td align="left" rowspan="2">MMP-13</td><td align="left" rowspan="2">Collagenase-3</td><td align="left">CCL7</td><td align="left">Regulation of chemokine signaling</td><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td align="left">CXCL12 (SDF-1&#x003b1;)</td><td align="left"/><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left" rowspan="3">MMP-14</td><td align="left" rowspan="3">MT1-MMP</td><td align="left">CCL7</td><td align="left">Regulation of chemokine signaling</td><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td align="left">CXCL12 (SDF-1&#x003b1;)</td><td align="left"/><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left">Latent TGF-&#x003b2;1</td><td align="left">Pot. anti-inflammatory response</td><td align="left">[<xref ref-type="bibr" rid="CR67">67</xref>]</td></tr><tr><td align="left" rowspan="3">ADAM-10</td><td align="left" rowspan="3">CD156c</td><td align="left">IL-6R</td><td align="left">IL-6 trans-signaling</td><td align="left">[<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]</td></tr><tr><td align="left">EGF, betacellulin</td><td align="left">EGFR signaling</td><td align="left">[<xref ref-type="bibr" rid="CR82">82</xref>]</td></tr><tr><td align="left">VE-cadherin</td><td align="left">Junction protein degradation</td><td align="left">[<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td align="left" rowspan="5">ADAM-17</td><td align="left" rowspan="5">TACE</td><td align="left">proTNF-&#x003b1;</td><td align="left">TNF-&#x003b1; activation</td><td align="left">[<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]</td></tr><tr><td align="left">TNFR1, TNFR2</td><td align="left">TNFR shedding, TNF-&#x003b1; antagonization</td><td align="left">[<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td align="left">IL-6R</td><td align="left">IL-6 trans-signaling</td><td align="left">[<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]</td></tr><tr><td align="left">EPR, TGF-&#x003b1;, AREG, HB-EGF</td><td align="left">EGFR signaling</td><td align="left">[<xref ref-type="bibr" rid="CR82">82</xref>]</td></tr><tr><td align="left">L-selectin</td><td align="left">Leukocyte migration</td><td align="left">[<xref ref-type="bibr" rid="CR80">80</xref>]</td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Pro-inflammatory roles of metalloproteinases during neuroinflammation. MMPs directly and indirectly contribute to chemotactic gradients in the bloodstream and neutrophil (orange cells) recruitment at site of infection. ADAMs and MMPs contribute to adherens junction protein (AJP) and tight junction protein (TJP) degradation. MMPs further show specific cleavage of basal lamina components. Upon destruction of the BBB, neutrophils enter the central nervous system and further generate chemotactic gradients with secreted MMP-9 being able to cleave and activate IL-8. Collagenases further contribute to BBB leakage by degradation of the extracellular matrix (ECM). ADAMs and MMPs directly contribute to neuroinflammation by activating pro-inflammatory cytokines like IL-1&#x003b2; and TNF-&#x003b1; from microglia/macrophage (green cell). This illustration only summarizes the most important roles of ADAMs and MMPs in induction of neuroinflammation, a more thorough picture is found in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. For simplicity, the BBB is depicted without pericytes and astrocytes. Illustration design inspired by Khokha et al. [<xref ref-type="bibr" rid="CR15">15</xref>]</p></caption><graphic xlink:href="18_2019_3174_Fig1_HTML" id="MO1"/></fig></p><sec id="Sec5"><title>MMPs in neutrophil migration and cytokine signaling</title><sec id="Sec6"><title>MMPs in chemokine signaling</title><p id="Par34">To establish an effective immune reaction against invading pathogens, neutrophils must migrate efficiently along chemotactic gradients and extravasate from the blood vessels towards the site of infection. Metalloproteinases have been demonstrated to be involved in these processes not only by degrading ECM and promoting effector cell extravasation but also by regulation of chemotactic gradients [<xref ref-type="bibr" rid="CR15">15</xref>]. This was first demonstrated with MMP-9 shown to process an amino-terminal fragment of IL-8, thereby increasing its chemoattractant properties to more efficiently recruit neutrophils [<xref ref-type="bibr" rid="CR46">46</xref>]. On the other hand, MMP-2 was shown to inactivate monocyte chemotactic protein 3 (MCP3, also known as chemokine (C&#x02013;C motif) ligand 7, CCL7) by removing an amino-terminal tetrapeptide, converting it to an antagonist of its chemokine receptors [<xref ref-type="bibr" rid="CR47">47</xref>]. Conceptually, these findings showed that MMPs can not only act as effectors but also regulators of inflammatory responses [<xref ref-type="bibr" rid="CR47">47</xref>]. Subsequently, CCL7 has been also shown to be a specific substrate of MMP-1, -3, -13 and -14 but not MMP-8 and -9 [<xref ref-type="bibr" rid="CR48">48</xref>]. The closely related chemokines CCL2, CCL8 and CCL13 (MCP-1, -2 and -4) are proteolytically cleaved by MMP-1 and -3 (but not MMP-2 and -14) with the truncated products of CCL8 and CCL13 being potent antagonists of the their respective chemokine receptors [<xref ref-type="bibr" rid="CR48">48</xref>]. Apart from influencing the activity of C&#x02013;C motif chemokines, MMPs also contribute to CXC-chemokine function. Stromal cell-derived factor 1 alpha (SDF-1&#x003b1;, also known as CXCL12) is processed and inactivated by MMP-1, -2, -3, -9, -13 and -14 but not by MMP-7 and -8 [<xref ref-type="bibr" rid="CR49">49</xref>]. The truncated form of CXCL12 after MMP-2 processing demonstrates highly neurotoxic properties [<xref ref-type="bibr" rid="CR50">50</xref>]. An elegant study with single and double knockout mice for MMP-2 and MMP-9 revealed that these MMPs work synergistically in the initial step of neutrophil recruitment to injury sites by increasing the potency of CXC-chemokine ligand 5 (CXCL5) [<xref ref-type="bibr" rid="CR51">51</xref>]. Activation of murine LPS-induced CXC chemokine (LIX, similar to the human neutrophil-recruiting chemokine CXCL5 and CXCL8/IL-8) is dependent on MMP-8, with cleaved LIX promoting enhanced chemotaxis [<xref ref-type="bibr" rid="CR52">52</xref>]. Neutrophil infiltration at LPS-stimulated sites is clearly diminished in <italic>mmp8</italic><sup>&#x02212;<italic>/</italic>&#x02212;</sup> mice [<xref ref-type="bibr" rid="CR52">52</xref>]. The same study showed that MMP-8 itself is not required for the extravasation and migration of neutrophils, but plays a very crucial role in orchestrating the initial inflammatory response upon LPS stimulation, thereby indicating that chemoattractants rather than collagen are MMP-8&#x02019;s primary substrates [<xref ref-type="bibr" rid="CR52">52</xref>]. Nevertheless, collagens processed by MMP-8 can also act as chemotactic peptides during neutrophil chemotaxis [<xref ref-type="bibr" rid="CR53">53</xref>]. Both MMP-8 and -9 are reported to cleave CXCL5 and CXCL6, but no change in biological activity of CXCL6 was demonstrated [<xref ref-type="bibr" rid="CR54">54</xref>]. MMP-9, in contrast, potently inactivates CXCL5 by multiple cleavages, suggesting a regulatory role of MMP-9 in early activation with subsequent inactivation of CXCL5 [<xref ref-type="bibr" rid="CR54">54</xref>]. In addition to direct effects of MMPs on chemokines, MMPs might also regulate the expression of chemokine receptors, thereby providing an additional level by which these proteinases control leukocyte migration [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR55">55</xref>].</p><p id="Par35">Besides directly processing chemokines and altering their biological function, MMPs can also indirectly influence the availability and activity of chemokines by cleaving accessory macromolecules that bind them [<xref ref-type="bibr" rid="CR56">56</xref>]. Thereby, MMPs exhibit an additional way of regulating leukocyte migration [<xref ref-type="bibr" rid="CR5">5</xref>]. MMP-7 is involved in syndecan-1 cleavage, which in turn releases CXCL1 (also known as KC). Thereby, MMP-7 indirectly generates a chemotactic gradient that directs neutrophil migration to sites of injury [<xref ref-type="bibr" rid="CR56">56</xref>]. Consequently, neutrophil infiltration is massively reduced in <italic>mmp7</italic><sup>&#x02212;<italic>/</italic>&#x02212;</sup> mice at sites of injury because of impaired transepithelial migration [<xref ref-type="bibr" rid="CR56">56</xref>]. Other MMPs also regulate chemotactic gradients, but their role is less well understood. MMP-2 seems to be critical for establishing a CCL11 (eotaxin) chemotactic gradient during leukocyte recruitment, as allergen-induced asthmatic <italic>mmp2</italic><sup>&#x02212;<italic>/</italic>&#x02212;</sup> mice show leukocyte accumulation in lung parenchyma and decreased CCL11 levels [<xref ref-type="bibr" rid="CR57">57</xref>]. Notably, this indirect pro-inflammatory effect of MMP-2 is very distinct from the above discussed direct anti-inflammatory function via chemokine cleavage and inactivation [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. In addition to MMP-2, MMP-9 contributes to the generation of the chemotactic gradient in allergen-induced asthmatic mice, where <italic>mmp9</italic><sup>&#x02212;<italic>/</italic>&#x02212;</sup> mice showed diminished CCL11, CCL7 and CCL17 chemoattractant levels [<xref ref-type="bibr" rid="CR58">58</xref>]. In summary, these studies demonstrate that MMPs are important regulators of inflammation by controlling chemokine activity and chemotactic gradients, thereby manipulating leukocyte migration.</p></sec><sec id="Sec7"><title>MMPs in cytokine signaling</title><p id="Par36">Apart from generating chemotactic gradients and recruiting leukocytes to sites of infection, MMPs also have the capacity to directly activate and regulate cytokine signaling. The pro-inflammatory cytokine IL-1&#x003b2; needs proteolytic activation by the IL-1&#x003b2;-converting enzyme (ICE, more recently re-named to caspase-1) [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. After discovery of caspase-1-independent activation of IL-1&#x003b2; [<xref ref-type="bibr" rid="CR61">61</xref>], MMP-2, -3 and -9 were described to process human IL-1&#x003b2; precursor into biologically active forms [<xref ref-type="bibr" rid="CR62">62</xref>]. In addition, MMP-3&#x02014;to a lesser extent MMP-9, but not collagenases&#x02014;was found to degrade active IL-1&#x003b2; after longer incubation periods, indicating regulatory roles of MMPs in both IL-1&#x003b2; activation and inactivation [<xref ref-type="bibr" rid="CR62">62</xref>]. Under physiological conditions, conversion of the membrane-bound pro-TNF-&#x003b1; to its active and soluble form is attributed to TNF-&#x003b1;-converting enzyme (TACE, now known as ADAM17, also see next section) [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Even if ADAM17 is the most specific and best convertor of pro-TNF-&#x003b1;, MMP-7&#x02014;and to lesser but not physiologically relevant extent MMP-1 and -9&#x02014;harbors the capacity to cleave and activate pro-TNF-&#x003b1; and seems to act as another physiological TNF-&#x003b1; convertor [<xref ref-type="bibr" rid="CR65">65</xref>]. In contrast to the activation of these pro-inflammatory cytokines, MMPs (MMP-3, -9 and -14) are also able to activate transforming growth factor-&#x003b2;1 (TGF-&#x003b2;1) in vitro [<xref ref-type="bibr" rid="CR66">66</xref>&#x02013;<xref ref-type="bibr" rid="CR68">68</xref>], which restrains mononuclear inflammation [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>], thereby again indicating an overall regulatory effect of MMPs in inflammation.</p></sec></sec><sec id="Sec8"><title>ADAMs in infection and inflammatory responses</title><p id="Par37">TNF-&#x003b1;-converting enzyme (TACE; ADAM17) was originally thought to be a MMP, as it was effectively inhibited by synthetic metalloproteinase inhibitors [<xref ref-type="bibr" rid="CR71">71</xref>], but later found to belong the ADAM family and identified as ADAM17 [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. ADAM17 shows very distinct specificity for shedding membrane-bound pro-TNF-&#x003b1;, thereby releasing biologically active TNF-&#x003b1; [<xref ref-type="bibr" rid="CR65">65</xref>], with both pro-inflammatory and pro-apoptotic functions [<xref ref-type="bibr" rid="CR15">15</xref>]. In ADAM17-deficient cells, TNF-&#x003b1; release is reduced by 90%, indicating that ADAM17 is the principal TNF-&#x003b1; converting enzyme [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Soluble TNF-&#x003b1; signals via binding of TNF receptor 1 (TNFR1), whereas membrane-bound TNF-&#x003b1; acts preferentially through binding of TNFR2 [<xref ref-type="bibr" rid="CR72">72</xref>]. The regulation of TNF signaling by ADAM17 is even more complex, since ADAM17 also sheds TNFR1 and TNFR2 [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. These act as decoy receptors by sequestering soluble TNF-&#x003b1; away from their receptors [<xref ref-type="bibr" rid="CR15">15</xref>]. ADAM17 deficiency in myeloid cells protected mice from endotoxin-induced septic shock by preventing increased serum levels of TNF-&#x003b1; [<xref ref-type="bibr" rid="CR75">75</xref>]. As ADAM17-dependent TNF-&#x003b1; conversion is selectively inhibited by TIMP3 [<xref ref-type="bibr" rid="CR14">14</xref>], <italic>Timp3</italic><sup>&#x02212;<italic>/</italic>&#x02212;</sup> mice show enhanced TNF-&#x003b1; signaling with elevated IL-6 serum levels and increased mortality after LPS-induced sepsis [<xref ref-type="bibr" rid="CR76">76</xref>]. ADAM17&#x02014;but also ADAM10&#x02014;have been described to be involved in IL-6 trans-signaling by shedding IL-6 receptor (IL-6R), which in turn complexes with IL-6 and interacts with gp130-containing membrane receptors that are ubiquitously expressed on many cell types [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>].</p><p id="Par38">Most leukocytes express L-selectin on their surface, which is involved in their rolling on inflamed vascular endothelium, followed by firm adhesion and transmigration [<xref ref-type="bibr" rid="CR79">79</xref>]. L-selectin is rapidly cleaved near the leukocyte cell surface by ADAM17 [<xref ref-type="bibr" rid="CR79">79</xref>], during their transmigration [<xref ref-type="bibr" rid="CR15">15</xref>]. ADAM17-null neutrophils show slower rolling, better adhesion and faster recruitment to site of inflammation [<xref ref-type="bibr" rid="CR80">80</xref>] with impaired L-selectin shedding being responsible for early neutrophil recruitment [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>].</p><p id="Par39">In mucosal barriers, ADAM17 has been shown to be important for EGFR activation, with ADAM17 or EGFR-deficient mice showing similar features [<xref ref-type="bibr" rid="CR74">74</xref>]. Subsequently, ADAM17 was shown to be the major convertase of the EGFR ligands epiregulin, TGF-&#x003b1;, amphiregulin and heparin-binding EGF-like growth factors, whereas ADAM10 emerged as the major sheddase of EGF and betacellulin [<xref ref-type="bibr" rid="CR82">82</xref>]. In intestinal inflammation, ADAM17-dependent EGFR ligand shedding is necessary for the production of antimicrobial peptides by epithelial cells and later regeneration [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. ADAM17 has additionally been associated with shedding of L-selectin from activated T cells, thereby regulating the recruitment of adaptive immune cells [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par40">ADAMs are also able to manipulate immune signaling via ectodomain shedding of the Notch receptor, which is required for its activation [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. Notch activation by ADAM17 was found to regulate atopic barrier function and suppress epithelial cytokine synthesis [<xref ref-type="bibr" rid="CR86">86</xref>]. In addition, ADAM17 and ADAMTS12 were shown to be involved in neutrophil apoptosis during resolution of acute inflammation [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>].</p></sec><sec id="Sec9"><title>MMPs and microglia</title><p id="Par41">Microglia are brain-resident immune cells that are involved in important roles of the healthy, infected and injured brain, including post-natal neurodevelopment, neural plasticity and phagocytosis [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. Upon stimulation, microglia can be polarized into different microglial subsets [<xref ref-type="bibr" rid="CR91">91</xref>]. The polarization states can be roughly divided into classically activated (M1) microglia that adapt a pro-inflammatory phenotype by secreting TNF-&#x003b1;, IL-1&#x003b2;, IL-6 and IFN&#x003b3; [<xref ref-type="bibr" rid="CR92">92</xref>], and alternatively activated (M2) cells, which produce cytokines involved in inflammation termination, restoring homeostasis and promoting tissue repair [<xref ref-type="bibr" rid="CR91">91</xref>]. MMPs are expressed and produced by microglia at site of infection and inflammation [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. In macrophages, the two different subsets&#x02014;M1 and M2&#x02014;express different MMPs [<xref ref-type="bibr" rid="CR95">95</xref>]. MMP-9&#x02014;which depicts pro-inflammatory roles in BBB opening and cytokine activation&#x02014;is secreted by M2 microglia and involved as a remodeling factor during repair [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. <italic>Kohkha</italic> et al. further suggest that MMPs&#x02014;apart from being differentially expressed in M1 and M2 subsets&#x02014;might also contribute to phenotype polarization by regulating cytokine and growth factor availability [<xref ref-type="bibr" rid="CR15">15</xref>]. As microglia polarization towards the M2 phenotype gains interest as therapeutic strategy for different neurological disorders, understanding the critical role of metalloproteinases during this process needs further investigations.</p><p id="Par42">Collectively, these findings demonstrate the crucial role of metalloproteinases in initiation of neuroinflammation&#x02014;including BBB breakdown, chemokine activation with neutrophil recruitment, and pro-inflammatory cytokine production&#x02014;but also in inflammation termination and subsequent repair via chemokine and cytokine inactivation and involvement in angiogenesis, neurogenesis and gliosis after damage [<xref ref-type="bibr" rid="CR98">98</xref>&#x02013;<xref ref-type="bibr" rid="CR101">101</xref>]. Therefore, inhibition of metalloproteinase during acute inflammatory processes can lead to beneficial outcomes, whereas inhibition during repair processes might be detrimental [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>].</p></sec></sec><sec id="Sec10"><title>MMPs and ADAMs in infectious disease of the CNS</title><p id="Par43">The brain is protected from infectious agents by specialized barriers including the skull, the meninges and the restrictive BBB, making the brain a microbiologically sterile site under physiologic conditions [<xref ref-type="bibr" rid="CR104">104</xref>]. Subsequently, infectious disease of the CNS&#x02014;such as bacterial meningitis&#x02014;occur at comparatively low levels but might have detrimental consequences [<xref ref-type="bibr" rid="CR105">105</xref>]. As described above, metalloproteinases regulate barrier functions of the BBB but also of mucosal epithelium and play multiple roles in the initiation and regulation of inflammation, thereby being essentially involved in CNS infections.</p><sec id="Sec133"><title>Metalloproteinases in bacterial meningitis</title><sec id="Sec12"><title>Pathophysiology of brain injury during bacterial meningitis</title><p id="Par44">To establish a CNS infection, the bacterial pathogens have to successfully colonize the host before they gain access to the subarachnoid space or the brain parenchyma. The most common causative agents of bacterial meningitis&#x02014;<italic>Streptococcus pneumoniae</italic>, <italic>Neisseria meningitidis</italic> and <italic>Haemophilus influenzae</italic> type b [<xref ref-type="bibr" rid="CR106">106</xref>]&#x02014;colonize the human nasopharynx and are transmitted via the respiratory route [<xref ref-type="bibr" rid="CR105">105</xref>]. Most cases of bacterial meningitis originate from bacteremia, where the nasopharyngal pathogen gains access to the blood stream and subsequently crosses the BBB or blood&#x02013;CSF barrier (BCSFB). Other causative pathogens of bacterial meningitis&#x02014;which cause meningitis mostly in neonates, elderly and immunocompromized patients (group B <italic>Streptococcus</italic> (GBS), <italic>Escherichia coli</italic>, <italic>Listeria monocytogenes</italic>)&#x02014;colonize the intestinal mucosa from where they access the circulation and invade the brain [<xref ref-type="bibr" rid="CR105">105</xref>]. Bacterial meningitis might also arise from focal infection in the vicinity of the brain (i.e., otitis media, sinusitis, dental abscess), where local spread rather than bacteremia underlies bacterial brain invasion [<xref ref-type="bibr" rid="CR105">105</xref>]. Finally, breaches of the anatomical brain barriers (trauma or surgery) may also lead to bacterial meningitis.</p><p id="Par45">Among bacterial meningitis, pneumococcal meningitis (PM) is especially detrimental as it causes high mortality and leads to long-lasting neurofunctional deficits [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. Neurofunctional sequelae after PM include hearing loss, epilepsy, cerebral palsy, as well as behavioral and cognitive deficits [<xref ref-type="bibr" rid="CR107">107</xref>&#x02013;<xref ref-type="bibr" rid="CR109">109</xref>]. Brain damage during PM is characterized by cortical necrosis and apoptosis of dentate gyrus granular cell progenitors in the hippocampus, being in part responsible for behavioral and cognitive deficits [<xref ref-type="bibr" rid="CR110">110</xref>&#x02013;<xref ref-type="bibr" rid="CR114">114</xref>]. In experimental models, cortical necrosis is found as early as 18&#x000a0;h after infection and might arise as a consequence of focal and global ischemia [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. Neural cell death is caused by multiple factors including bacterial toxins and an excessive inflammatory reaction from the host [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR116">116</xref>&#x02013;<xref ref-type="bibr" rid="CR118">118</xref>]. Inflammatory mediators (cytokines, chemokines, reactive oxygen and nitrogen species, MMPs) released from recruited neutrophils, endothelial cells, leptomeningeal macrophages and brain-resident microglia and astrocytes contribute to pathogen eradication but also act as neurotoxins and induce neuronal damage [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>]. Moreover, PM induces damage to hair cells and spiral ganglion neurons in the inner ear [<xref ref-type="bibr" rid="CR121">121</xref>&#x02013;<xref ref-type="bibr" rid="CR123">123</xref>] provoking sensorineural&#x000a0;hearing impairments in up to 30% of survivors [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR125">125</xref>]. In an infant rat PM model, increased CSF levels of TNF-&#x003b1; during acute infection were positively correlated with increased hearing loss in surviving animals [<xref ref-type="bibr" rid="CR122">122</xref>].</p><p id="Par46">The pathogenesis and involvement of inflammatory processes in inducing brain damage during meningitis have been intensively studied in different animal models. Upon bacterial invasion into the CNS, a wide range of cytokine is produced and secreted into the CSF [<xref ref-type="bibr" rid="CR126">126</xref>]. In experimental pneumococcal meningitis, increased CSF levels of TNF-&#x003b1; and MMP-9 are already detected at 4&#x000a0;h after infection and peaked at 12&#x000a0;h after infection [<xref ref-type="bibr" rid="CR127">127</xref>]. Since levels of TNF-&#x003b1;, IL-1&#x003b2;, IL-6 and IL-8 in the CSF increase before evidence of neutrophil recruitment, brain-resident cells are considered to contribute significantly to cytokine production [<xref ref-type="bibr" rid="CR126">126</xref>]. As a result of bacterial proliferation, an excessive inflammatory reaction takes place in the CSF with BBB breakdown causing brain edema via leakage of plasma into the CNS, increased intracranial pressure, hydrocephalus and cerebral ischemia [<xref ref-type="bibr" rid="CR116">116</xref>]. In patients with bacterial meningitis, cerebrovascular complications are frequently observed [<xref ref-type="bibr" rid="CR124">124</xref>] with vasculitis being the cause for cerebral infarction, hemorrhages and subsequent cortical damage during meningitis [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR124">124</xref>].</p></sec><sec id="Sec13"><title>Metalloproteinases in the pathogenesis of bacterial meningitis</title><p id="Par47">Data from clinical and experimental studies have shed light onto the crucial role of metalloproteinases during pathogenesis of bacterial meningitis and other neuro-infectious diseases. Metalloproteinases&#x02014;expressed or activated in response to the invading pathogen&#x02014;contribute to acute neuroinflammatory reaction and damage upon bacterial invasion but might also be involved later during the disease in the resolution of inflammation and repair mechanisms [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR127">127</xref>&#x02013;<xref ref-type="bibr" rid="CR129">129</xref>]. During bacterial meningitis, the expression and activation of metalloproteinases and their inhibitors are altered compared to physiologic conditions. During experimental PM in infant rats, MMP-8 and MMP-9 are transcriptionally upregulated in CSF cells, whereas the expression of MMP-2 and MMP-7 remains unaffected. In brain tissue, expression of MMP-3, -8, -9, -12, -13 and -14 was significantly upregulated (100- to 1000-fold), while expression levels of MMP-2 and MMP-7 remained unchanged [<xref ref-type="bibr" rid="CR127">127</xref>]. The upregulation of MMP-8 (mostly released from infiltrating neutrophils) is a specific hallmark of bacterial meningitis, which is not found in other neuroinflammatory disease [<xref ref-type="bibr" rid="CR130">130</xref>]. MMP-8 induces increased barrier permeability via proteolytic cleavage of the tight junction protein occludin in meningococcal neuroinfection [<xref ref-type="bibr" rid="CR131">131</xref>]. Other experimental data of meningitis caused by heat-inactivated <italic>N. meningitidis</italic> showed a significant upregulation of MMP-9 mRNA expression with stable MMP-2 and MMP-7 expression [<xref ref-type="bibr" rid="CR41">41</xref>]. On the protein level, MMP-9 in the CSF correlated with TNF-&#x003b1; levels, with a concentration peak for both at 12&#x000a0;h after intracisternal infection with <italic>S. pneumoniae</italic> [<xref ref-type="bibr" rid="CR127">127</xref>]. MMP-9 in the CSF was detected as early as 15&#x000a0;min after intracisternal infection, indicating its early release from brain-resident cells in this experimental model. Further recruitment and infiltration of neutrophils contribute to the peak MMP-9 levels at 12&#x000a0;h after infection [<xref ref-type="bibr" rid="CR127">127</xref>]. Gelatinase activity (MMP-2 and/or MMP-9) has been associated with the occurrence of cortical necrotic lesions in experimental PM [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR132">132</xref>]. During the initiation of neuroinflammation, ADAM17 plays a crucial role in releasing TNF-&#x003b1;, which in turn acts as a stimulus to induce MMP upregulation via a positive feedback loop [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR133">133</xref>]. The fact that MMP-7&#x02014;being the second most potent TNF-&#x003b1; activator apart from ADAM17 [<xref ref-type="bibr" rid="CR65">65</xref>]&#x02014;remains unchanged in bacterial meningitis [<xref ref-type="bibr" rid="CR127">127</xref>] emphasizes the importance of ADAM17 during this early neuroinflammatory process. In addition to increased TNF-&#x003b1; and MMP-9 levels, TIMP-1 expression is also increased in the CSF of infant rats with PM, however, with a short delay [<xref ref-type="bibr" rid="CR23">23</xref>]. TIMPs are suggested to regulate protein degradation and cytokine shedding during PM, thereby controlling metalloproteinase-induced neuroinflammation. In experimental PM, the upregulation of MMP-9, however, exceeds the compensatory effect of TIMP-1 during the acute phase. This imbalance between MMPs and TIMPs during bacterial meningitis has, therefore, been implicated as a key event during pathophysiology of the disease [<xref ref-type="bibr" rid="CR23">23</xref>]. In an experimental model of cerebral ischemia, MMP-9-deficient mice showed BBB preservation and reduced levels of tight junction protein degradation with subsequent better outcome [<xref ref-type="bibr" rid="CR134">134</xref>]. MMP-9 deficiency during experimental PM, however, was shown to be associated with impaired bacterial clearance from blood and spleen, without showing an impact on clinical course of the disease, leukocyte infiltration of the subarachnoid space or bacterial titers in the brain [<xref ref-type="bibr" rid="CR135">135</xref>]. Non-infectious experimental models of brain damage have shown a direct effect of MMP-9 on laminin degradation and associated hippocampal apoptosis [<xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR137">137</xref>].</p><p id="Par48">Matrix metalloproteinase expression profiles in patients with bacterial meningitis are consistent with the data generated in experimental settings. In patients with bacterial meningitis, CSF levels of MMP-1, -3, -7, -8, -9 and -10 have been found to be elevated, whereas CSF levels of MMP-2 remain unaffected [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR138">138</xref>&#x02013;<xref ref-type="bibr" rid="CR143">143</xref>]. Similar to animal models, TIMP-1 levels have also been found to be upregulated, whereas TIMP-4 was significantly downregulated compared to control patients [<xref ref-type="bibr" rid="CR142">142</xref>]. One week after infection, TIMP-1 continues to be highly expressed, whereas MMP-9 is reduced compared to the acute phase of infection [<xref ref-type="bibr" rid="CR144">144</xref>]. In pediatric PM, MMP-9 levels were found to correlate with CSF cell counts, with high CSF MMP-9 levels being a risk factor for fatal outcome or development of neurologic sequelae [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]. The causative pathogen determines the inflammatory response in patients with bacterial meningitis. Pneumococcal meningitis is associated with significantly increased mortality and elevated levels of IFN-&#x003b3;, MCP-1 and MMP-9 compared to meningitis caused by <italic>N. meningitidis</italic> or <italic>H. influenzae</italic> [<xref ref-type="bibr" rid="CR145">145</xref>].</p><p id="Par49">Tuberculous meningitis (TBM), which arises rarely as an extrapulmonary form of tuberculosis, is associated with neurofunctional complications [<xref ref-type="bibr" rid="CR146">146</xref>]. In patients with TBM, levels of MMP-2 and MMP-9 were found to be elevated, and high levels of MMP-9 were associated with late neurofunctional deficits [<xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR148">148</xref>]. Adjuvant dexamethasone during TBM was shown to reduce MMP-9 levels early in treatment and might represent one way by which dexamethasone reduces mortality in TBM [<xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR150">150</xref>]. Despite the beneficial effect of dexamethasone in terms of mortality, it could not successfully prevent severe disabilities [<xref ref-type="bibr" rid="CR150">150</xref>].</p></sec></sec><sec id="Sec14"><title>MMPs and ADAMs in viral neuro-infectious diseases</title><p id="Par50">The involvement of metalloproteinase in BBB integrity during viral neuroinfections has been intensively reviewed elsewhere [<xref ref-type="bibr" rid="CR151">151</xref>]. Clinical data from patients with viral meningitis report elevated CSF levels of MMP-9 and TIMP-1 compared to control patients, with MMP-9 levels correlating to neutrophil cell number in CSF [<xref ref-type="bibr" rid="CR152">152</xref>]. Involvement of metalloproteinases during viral neuroinfection has mostly been analyzed in experimental studies, though.</p><p id="Par51">Japanese encephalitis virus (JEV) is an arthropod-borne virus and a major cause of acute encephalopathy in children [<xref ref-type="bibr" rid="CR153">153</xref>]. In vitro, MMP-9 expression after JEV infection is mediated via NF-&#x003ba;B activation and the generation of ROS [<xref ref-type="bibr" rid="CR153">153</xref>]. The expression of MMP-2, -7 and -9, as well as TIMP-1 and -3 is upregulated in mice infected with JEV and their overexpression is associated with disease severity [<xref ref-type="bibr" rid="CR154">154</xref>].</p><p id="Par52">In experimental herpes-simplex virus encephalitis (HSE), MMP-9 is upregulated and insufficiently counterbalanced by TIMP-1 resulting in a loss of collagen type IV, indicating MMP-9&#x02019;s role during the pathogenesis of HSE [<xref ref-type="bibr" rid="CR155">155</xref>].</p><p id="Par53">In vitro, West Nile virus (WNV)-infected human endothelial cells show significant upregulation of multiple MMPs with subsequent loss of tight junction proteins, an effect successfully prevented by the MMP inhibitor GM6001 [<xref ref-type="bibr" rid="CR156">156</xref>]. MMP-9 levels are also found to be elevated in WNV-infected mice as well as in patients, suggesting that MMP-9 plays a role in mediating WNV entry into the CNS [<xref ref-type="bibr" rid="CR157">157</xref>].</p><p id="Par54">During HIV infection, a CCL2-dependent mechanism was postulated to be involved in infiltration of HIV-infected leukocytes into the CNS causing neuropathology. In vitro, this mechanism seems to rely on MMP-2 and -9 upregulation with an associated reduction of tight junction proteins [<xref ref-type="bibr" rid="CR158">158</xref>]. In experimental HIV infection, the envelope protein gp120 increased MMP-2 and -9 expression with subsequent laminin and claudin-5 reduction and causing increased BBB permeability [<xref ref-type="bibr" rid="CR159">159</xref>]. In patients with HIV-associated dementia, CSF levels of MMP-2, -7 and 9 are increased and might reflect a link to symptomatic neurological disease [<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]. Increased MMP activity with its detrimental effects on BBB integrity might contribute to transendothelial migration of HIV-infected cells into the CNS and development of HIV-associated neurologic damage [<xref ref-type="bibr" rid="CR161">161</xref>].</p><p id="Par55">Mouse adenovirus type-1 (MAV-1) infection increases levels of MMP-2 and -9 in brains [<xref ref-type="bibr" rid="CR162">162</xref>]. Additional ex vivo data revealed that MMP-2 and -9 are produced by astrocytes and microglia in response to mouse encephalitic adenovirus-1, which might contribute to BBB disruption and encephalitis [<xref ref-type="bibr" rid="CR163">163</xref>]. MAV-1 may also induce BBB breakdown by reducing surface expression of TJ proteins occludin and claudin-5 [<xref ref-type="bibr" rid="CR164">164</xref>]. Murine coronavirus-induced viral encephalitis induces expression of MMP-3 and -12 plus TIMP-1, with MMP-3 expression exclusively localized in astrocytes, whereas TIMP-1 originates from infiltrating cells [<xref ref-type="bibr" rid="CR165">165</xref>]. Increased MMP and TIMP levels are also associated with increased viral replication during neurotropic mouse hepatitis infection [<xref ref-type="bibr" rid="CR166">166</xref>].</p></sec><sec id="Sec15"><title>MMP and ADAM inhibitors as potential treatment options in bacterial meningitis</title><p id="Par56">Since MMPs and ADAMs are central regulators and mediators during neuroinflammation and development of neuronal damage in bacterial meningitis, inhibition of theses enzymes during acute infection has been postulated as a promising therapeutic intervention to improve disease outcome. Over the last three decades, many different inhibitors were tested in rodent models of bacterial meningitis (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>MMP and ADAM inhibitors improve acute and neurofuncitonal outcome in rodent bacterial meningitis.&#x000a0;Many data derive from proof-of-principle studies with early- or pretreatment and only few assessed adjuvant metalloproteinase inhibition with concomitant application of the inhibitors together with the antibiotic therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Inhibitor (time of initiation)</th><th align="left">Inhibitory profile</th><th align="left">Causative pathogen</th><th align="left">Beneficial effects</th><th align="left">Neg. effects</th><th align="left">Clinic. tested</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">BM-94 (pretreatment)</td><td align="left">Broad spectrum</td><td align="left"><p>Rat-MM</p><p>Mouse-MM</p></td><td align="left"><p>BBB breakdown &#x02193;, ICP &#x02193;</p><p>BBB breakdown &#x02193;, MMP-9 &#x02193;, intracerebral bleeding &#x02193;</p></td><td align="left"/><td align="left"/><td align="left"><p>[<xref ref-type="bibr" rid="CR172">172</xref>]</p><p>[<xref ref-type="bibr" rid="CR169">169</xref>]</p></td></tr><tr><td align="left"><p>GM6001</p><p>(0 hpi)</p><p>(24 hpi)</p></td><td align="left">Broad spectrum</td><td align="left"><p>Rat-PM</p><p>Rat-PM</p></td><td align="left"><p>Cortical necrosis &#x02193;, MMP-9 &#x02193;, TNF-&#x003b1; &#x02193;,</p><p>Cell death in cortex and hippocampus &#x02193;, Clinical status &#x02191;, MMP-9 &#x02193;, brain water content &#x02193;, learning/memory &#x02191;</p></td><td align="left"/><td align="left"/><td align="left"><p>[<xref ref-type="bibr" rid="CR128">128</xref>]</p><p>[<xref ref-type="bibr" rid="CR177">177</xref>]</p></td></tr><tr><td align="left">BB1001 (3 hpi; symptom onset)</td><td align="left">Broad spectrum plus ADAM17</td><td align="left">Rat-PM</td><td align="left">Cortical necrosis &#x02193;, hippo. apoptosis &#x02193;, learning/memory &#x02191;</td><td align="left"/><td align="left"/><td align="left">[<xref ref-type="bibr" rid="CR127">127</xref>]</td></tr><tr><td align="left">TNF484 (pretreatment)</td><td align="left">Broad spectrum plus ADAM17</td><td align="left">Rat-PM</td><td align="left">Cortical necrosis &#x02193;, seizures &#x02193;, TNF-&#x003b1; &#x02193;, collagen deg. &#x02193;</td><td align="left">Mortality &#x02191; for high dose</td><td align="left"/><td align="left">[<xref ref-type="bibr" rid="CR132">132</xref>]</td></tr><tr><td align="left">Ro 32-7315 (3 hpi)</td><td align="left">ADAM17&#x02009;&#x0003e;&#x02009;broad spectrum</td><td align="left">Rat-PM</td><td align="left">Cortical necrosis &#x02193;, hippo. apoptosis &#x02193;, weight loss &#x02193;, TNF-&#x003b1; &#x02193;, IL-6 &#x02193;</td><td align="left">Mortality &#x02191;</td><td align="left">Yes</td><td align="left">[<xref ref-type="bibr" rid="CR167">167</xref>]</td></tr><tr><td align="left"><p>Trocade&#x02122; (Ro 32-3555)</p><p>(3 hpi)</p></td><td align="left">Collagenase, part. gelatinase</td><td align="left">Rat-PM</td><td align="left">Cortical necrosis &#x02193;, hippo. apoptosis &#x02193;, mortality &#x02193;, TNF-&#x003b1; &#x02193;, IL-1&#x003b2; &#x02193;, collagen deg. &#x02193;</td><td align="left"/><td align="left">Yes</td><td align="left">[<xref ref-type="bibr" rid="CR167">167</xref>]</td></tr><tr><td align="left">RS-130830 (3 hpi)</td><td align="left">MMP-2, -3, -8, -9, -12, -13 and -14</td><td align="left">Rat-PM</td><td align="left">Cortical necrosis &#x02193;, IL-1&#x003b2; &#x02193;, IL-10 &#x02193;, weight loss &#x02193;, CSF WBCs &#x02193;</td><td align="left"/><td align="left">Yes</td><td align="left">[<xref ref-type="bibr" rid="CR168">168</xref>]</td></tr><tr><td align="left">Doxycycline (symptom onset)</td><td align="left">Broad spectrum plus ADAM17</td><td align="left">Rat-PM</td><td align="left">Cortical necrosis &#x02193;, mortality &#x02193;, TNF-&#x003b1; &#x02193;, BBB breakdown &#x02193;, SGN loss &#x02193;, hearing loss &#x02193;</td><td align="left"/><td align="left">Yes</td><td align="left">[<xref ref-type="bibr" rid="CR173">173</xref>]</td></tr><tr><td align="left">Trocade&#x02122;&#x02009;+&#x02009;Daptomycin (symptom onset)</td><td align="left">Colagenase, part. gelatinase, bacteriolysis inhibition</td><td align="left">Rat-PM</td><td align="left">Cortical necrosis &#x02193;, hippo. apoptosis &#x02193;, clinical status &#x02191;, TNF-&#x003b1; &#x02193;, IL-6 &#x02193;, IL-1&#x003b2; &#x02193;, IL-10 &#x02193;, learning and memory &#x02191;, hearing loss &#x02193;, bacillary clearance &#x02191;</td><td align="left"/><td align="left">Yes</td><td align="left">[<xref ref-type="bibr" rid="CR174">174</xref>]</td></tr><tr><td align="left">SB-3CT</td><td align="left">Gelatinases</td><td align="left">Mouse-TBM</td><td align="left">MMP-9 &#x02193;, bacillary clearance &#x02191;</td><td align="left"/><td align="left"/><td align="left">[<xref ref-type="bibr" rid="CR146">146</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>MM</italic> meningococcal meningitis, <italic>PM</italic> pneumococcal meningitis, <italic>TBM</italic> tuberculous meningitis, <italic>BBB</italic> blood&#x02013;brain barrier, <italic>ICP</italic> intra-cranial pressure, <italic>CSF</italic> cerebrospinal fluid, <italic>WBCs</italic> white blood cells, <italic>SGN</italic> spiral ganglion neurons</p></table-wrap-foot></table-wrap></p><sec id="Sec16"><title>Neuroinflammation and BBB breakdown</title><p id="Par57">Matrix metalloproteinases and ADAMs function as ECM degrading enzymes and sheddases, thereby controlling BBB breakdown and production of inflammatory cytokines [<xref ref-type="bibr" rid="CR15">15</xref>]. In experimental bacterial meningitis, MMP and ADAM inhibitors significantly reduce CSF levels of MMPs and pro-inflammatory cytokines (TNF-&#x003b1;, IL-6, IL-1&#x003b2;, IL-10) [<xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR167">167</xref>&#x02013;<xref ref-type="bibr" rid="CR169">169</xref>]. Notably, CSF levels of TNF-&#x003b1; are also significantly reduced by MMP inhibitors (MMPIs) without specificity for ADAM17 (i.e., Trocade) [<xref ref-type="bibr" rid="CR167">167</xref>], indicating that MMPIs are able to indirectly reduce pro-inflammatory cytokine production apart from direct ADAM17 inhibition. MMPIs partially preserved BBB integrity by preventing ECM protein degradation [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]. In a PM mouse model, TNF484 reduced neuroinflammation, thereby improving survival in animals without antibiotic therapy [<xref ref-type="bibr" rid="CR170">170</xref>]. Notably, there are remarkable differences in different mouse and rat strains in terms of BBB breakdown prevention by metalloproteinase inhibitors after LPS-induced neuroinflammation [<xref ref-type="bibr" rid="CR171">171</xref>].</p></sec><sec id="Sec17"><title>Cortical necrosis</title><p id="Par58">As a consequence of bacterial meningitis and its associated inflammatory reaction, cerebrovascular complications are frequently observed in patients [<xref ref-type="bibr" rid="CR124">124</xref>]. Focal ischemia caused by vasculitis results in cortical necrosis during meningitis [<xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]. Breakdown of the BBB during the excessive neuroinflammatory reaction is a crucial step in the development of cerebral ischemia [<xref ref-type="bibr" rid="CR116">116</xref>]. Since metalloproteinases are central regulators of BBB breakdown during bacterial meningitis (discussed above), their inhibition during the acute disease is a valuable therapeutic strategy to reduce cortical necrosis. Pre-treatment or treatment early in the course of disease with MMPIs is associated with reduced cortical necrosis in pneumococcal meningitis [<xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR173">173</xref>] and with lower rates of intracerebral hemorrhage in meningococcal meningitis [<xref ref-type="bibr" rid="CR169">169</xref>]. This neuroprotective effect is, however, reduced when the application of the inhibitors is delayed until the time of antibiotic therapy at the first appearance of disease symptoms [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR174">174</xref>]. The early inhibition of MMPs during bacterial meningitis might be responsible for an overall reduction of the neuroinflammatory reaction with reduced BBB breakdown and cytokine production, thereby limiting the pathophysiological consequences of the disease [<xref ref-type="bibr" rid="CR116">116</xref>].</p></sec><sec id="Sec18"><title>Hippocampal apoptosis</title><p id="Par59">Apoptosis of immature neurons in the dentate gyrus of the hippocampus during bacterial meningitis is caused by bacterial toxins, but also by an excessive inflammatory reaction from the host [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR116">116</xref>&#x02013;<xref ref-type="bibr" rid="CR118">118</xref>]. Several metalloproteinase inhibitors that inhibit ADAM17 (i.e., BB1001, Ro 32-7315) were found to prevent hippocampal apoptosis [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]. However, other ADAM17 inhibitors were unable to prevent neural cell death in the hippocampus [<xref ref-type="bibr" rid="CR132">132</xref>]. On the other hand, Trocade&#x02014;without having a specific ADAM17-inhibitory profile&#x02014;successfully prevented hippocampal apoptosis [<xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR174">174</xref>]. As MMP-9 is directly involved in hippocampal cell death via the degradation of laminin [<xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR137">137</xref>], inhibition of MMP-9&#x02014;rather than ADAM17&#x02014;might explain this neuroprotective effect of Trocade during bacterial meningitis. The protective effect on hippocampal neurons is lower&#x02014;but still present&#x02014;when BB1001 or Trocade therapy is initiated together with antibiotics at time of symptom onset [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR174">174</xref>].</p></sec><sec id="Sec19"><title>Neurofunctional outcome</title><p id="Par60">Apoptosis of dentate gyrus granular cell progenitors found in the hippocampus of humans [<xref ref-type="bibr" rid="CR114">114</xref>] and animal models with bacterial meningitis [<xref ref-type="bibr" rid="CR175">175</xref>, <xref ref-type="bibr" rid="CR176">176</xref>] correlates with behavioural and learning deficits [<xref ref-type="bibr" rid="CR110">110</xref>&#x02013;<xref ref-type="bibr" rid="CR113">113</xref>], with increased hippocampal apoptosis being associated with impaired learning and memory performance in rat PM [<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. Protection from hippocampal apoptosis by BB1001 improved learning performance in rats with PM [<xref ref-type="bibr" rid="CR127">127</xref>]. Similarly, in PM-infected rats treated with Trocade plus daptomycin, the observed reduction in hippocampal apoptosis was associated with a significant improvement of learning and memory function [<xref ref-type="bibr" rid="CR174">174</xref>]. GM6001 therapy significantly protected hippocampal neurons and prevented PM-induced learning and memory impairments in neonatal rats [<xref ref-type="bibr" rid="CR177">177</xref>]. Notably, all three therapies also significantly protected from cortical necrosis [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR174">174</xref>, <xref ref-type="bibr" rid="CR177">177</xref>], which might also positively influence learning and memory performance after PM. Correspondingly, in adult rats, MMP-2 and -9 inhibition further prevented cognitive impairment after PM possibly due to the observed successful preservation of BBB integrity during acute infection [<xref ref-type="bibr" rid="CR178">178</xref>].</p></sec><sec id="Sec20"><title>Bacterial meningitis-induced hearing loss</title><p id="Par61">Bacterial meningitis induces sensorineural hearing loss by damaging hair cells and spiral ganglion neurons in the inner ear [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR123">123</xref>]. In PM, CSF levels of TNF-&#x003b1; during acute infection are positively correlated with increased hearing threshold after infection [<xref ref-type="bibr" rid="CR122">122</xref>]. Treatment with doxycycline or Trocade plus daptomycin significantly reduces CSF levels of TNF-&#x003b1; and other pro-inflammatory cytokines and significantly improves hearing thresholds after PM [<xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR174">174</xref>]. Doxycycline&#x02014;with its broad spectrum MMP inhibition profile&#x02014;preserves spiral ganglion neurons from PM-induced cell death [<xref ref-type="bibr" rid="CR173">173</xref>]. The overall reduction of neuroinflammation in both therapies might be attributable to a reduced concentration of ototoxic compounds in the cochlear duct, thereby preventing ototoxic damage in spiral ganglion neurons and hair cells of the cochlea [<xref ref-type="bibr" rid="CR174">174</xref>].</p></sec><sec id="Sec21"><title>Detrimental effects after metalloproteinase inhibition</title><p id="Par62">Two metalloproteinase inhibitors&#x02014;Ro 32-7315 and high-dose TNF484, both with high specificity for ADAM17&#x02014;were reported to increase mortality during acute bacterial meningitis when administrated early after infection [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]. In an experimental model of PM with TNF-&#x003b1;-deficient mice, mortality was significantly increased despite treatment with antibiotics, indicating that TNF-&#x003b1; may play an essential role during infection and inflammation, being necessary for host defense in the early stages of infection [<xref ref-type="bibr" rid="CR179">179</xref>]. In PM, TNF-&#x003b1; inhibition by very potent ADAM17 inhibitors might, therefore, be rather detrimental than beneficial despite being neuroprotective in survivors, especially when applied at a time when TNF-&#x003b1; is a major contributor of the initial host response.</p></sec></sec></sec><sec id="Sec22"><title>Matrix metalloproteinases in multiple sclerosis</title><p id="Par63">Multiple sclerosis (MS) is a chronic autoimmune disease of the CNS, leading to progressive deterioration of motor, sensory, vegetative and cognitive functions [<xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR181">181</xref>]. The pathogenesis of MS encompasses both features of acute and subacute inflammation, and of chronic neurodegeneration, mainly as a result of the former. Because of these similarities with neuroinfectious disease with subsequent neuroinflammation and brain damage, MS is also covered in the present review.</p><p id="Par64">There are more than 2.3 million patients worldwide, making MS the most important neurological diseases of young adulthood [<xref ref-type="bibr" rid="CR180">180</xref>]. The disease affects predominantly Caucasians with highest prevalence in populations of Northern European origin. The cause of MS remains unknown, while there is strong evidence for an interplay of genetic and environmental factors (smoking, lack of sun exposure/vitamin D deficiency, Epstein&#x02013;Barr virus (EBV) infection) responsible for susceptibility and course of disease [<xref ref-type="bibr" rid="CR180">180</xref>, <xref ref-type="bibr" rid="CR181">181</xref>]. The classical understanding of MS pathogenesis is based on three essential paradigms. (1) Focal demyelination in the white matter is the predominant pathogenetic feature. (2) MS occurs in subtypes that are pathogenetically distinct from each other: primary progressive MS (PPMS) with development of disability from onset of disease; relapsing&#x02013;remitting MS (RRMS) with alternation between acute deterioration and clinical stable phases; and secondary progressive MS (SPMS) with continuous disability worsening between or without intermittent relapse in patients earlier diagnosed with RRMS. (3) MS is a T cell dependent disease.</p><p id="Par65">However, in recent years an increasing body of evidence has led to a modification and extension of these paradigms. Demyelination is not restricted to white matter, but extends steadily into the grey matter in the course of disease [<xref ref-type="bibr" rid="CR182">182</xref>]. Neuronal loss as the cellular substrate of disability worsening occurs in the course of demyelination, but to an even larger extent outside and independent of focal demyelination. Additionally, it seems that a relevant fraction of patients have a form of MS where no white matter demyelination occurs [<xref ref-type="bibr" rid="CR183">183</xref>]. Further, the phenotypic characterization of MS subtypes is not based on distinct molecular mechanisms. According to the current understanding, there is a continuum of several pathogenetic pathways, which may predominate at certain stages and disease duration [<xref ref-type="bibr" rid="CR180">180</xref>]. Lastly, the success of B-cell targeting therapies has revolutionized our understanding on the autoimmune response in MS: B cells seem to orchestrate and drive the disease directly and indirectly via T cells and other cells in acute and progressive phases [<xref ref-type="bibr" rid="CR184">184</xref>].</p><p id="Par66">The important role of MMPs as effector molecules of inflammatory tissue damage has been recognized in the 1990s of the last century. The progress of our understanding of MS pathogenesis has rather increased their importance and added to the complexity of their regulation in the pathogenesis of disease.</p><p id="Par67">Focal opening of the BBB is one of the initial events in the course of acute exacerbation of MS, followed by invasion of blood-derived leucocytes into the perivascular brain parenchyma, eventually leading to the formation of focal lesions that manifest clinically as attacks. Leukocytes, as well as cells that form the BBB (endothelial cells, astrocytes), produce MMPs and TIMPs, and BBB leakage is a result of MMP upregulation that is not any more compensated by TIMP activity [<xref ref-type="bibr" rid="CR185">185</xref>]. Basal membrane type IV collagen as the primary barrier structure at the BBB is a main substrate for gelatinases (MMP-2 and -9), which makes them specific effector molecules of leukocyte extravasation into the brain parenchyma. In MS lesions, upregulation of MMP-1, -2, -3, -7 and -9 was demonstrated by immunohistochemistry [<xref ref-type="bibr" rid="CR186">186</xref>&#x02013;<xref ref-type="bibr" rid="CR188">188</xref>] and on the transcriptional level [<xref ref-type="bibr" rid="CR189">189</xref>], and correlated with inflammatory activity in lesions.</p><p id="Par68">In the experimental autoimmune encephalitis (EAE) model of MS, the upregulation of MMP-7 and -9 correlated with the course of disease severity [<xref ref-type="bibr" rid="CR190">190</xref>]. In contrast, knockout mice deficient for MMP-9 were less susceptible to EAE induction [<xref ref-type="bibr" rid="CR191">191</xref>]. In the delayed-type hypersensitivity (DTH) rat model, protein and transcriptional expression of several MMPs was increased. Moreover, microinjection of MMP-7, -8 and -9 into brain parenchyma led to demyelination and axonal damage, the latter in part independent of the former. Axonal damage continued even when the integrity of the BBB was re-established [<xref ref-type="bibr" rid="CR192">192</xref>, <xref ref-type="bibr" rid="CR193">193</xref>]. The fact that MMPs may cause direct neuronal damage is very important for the concept of clinical progression of MS. Their increased expression also in chronic phases of lesions development [<xref ref-type="bibr" rid="CR189">189</xref>] may contribute to chronic smouldering neuronal loss, and eventually lead to progressive deterioration of neurological functions. On the other hand, CSF analysis in patients with &#x02018;active progressive MS&#x02019; (having either a relapse the previous year or presence of lesions with gadolinium enhancement at baseline MRI) has higher levels of MMP-9 and CXCL13 (a B-cell activation marker) than inactive progressive MS patients. This coincides with higher levels of neurofilament light chain as a measure of ongoing axonal damage, and of MBP as indicator of demyelination [<xref ref-type="bibr" rid="CR194">194</xref>].</p><p id="Par69">Several groups have demonstrated an increase of MMP-9 in CSF [<xref ref-type="bibr" rid="CR195">195</xref>, <xref ref-type="bibr" rid="CR196">196</xref>] and in blood of MS patients [<xref ref-type="bibr" rid="CR185">185</xref>, <xref ref-type="bibr" rid="CR197">197</xref>]. The levels correlated with disease activity (higher in RRMS/SPMS vs PPMS [<xref ref-type="bibr" rid="CR195">195</xref>], or MRI activity [<xref ref-type="bibr" rid="CR185">185</xref>, <xref ref-type="bibr" rid="CR197">197</xref>]. In a longitudinal study of SPMS patients, the increase of MMP-9/TIMP-1 ratio preceded the occurrence of new gadolinium-enhancing lesions [<xref ref-type="bibr" rid="CR198">198</xref>]. This study showed also higher median levels of TIMP-1. MMP-9 trended lower in patients receiving IFN&#x003b2; compared to placebo recipients. Similarly, steroids treatment used as interventional therapy during acute exacerbation of MS led to a decrease of MMP-9 in CSF with the most prominent effect in patients with gadolinium-enhancing lesions, further supporting its functional role in BBB breakdown [<xref ref-type="bibr" rid="CR199">199</xref>]. Moreover, quantitative PCR analysis revealed that IFN&#x003b2; therapy downregulated the expression of MMP-2 and -9 in blood leukocytes. Patients that developed neutralizing antibodies against IFN&#x003b2; showed an increase of these MMPs in circulation, supporting the concept that these antibodies reduce the therapeutic efficacy IFN&#x003b2; therapy [<xref ref-type="bibr" rid="CR200">200</xref>].</p><p id="Par70">Most work on MMPs in MS is restricted to MMP-9 and -2. This is mainly due to the fact that these members of the MMP family could be quantified easily and with highest sensitivity by zymography, while for all other MMPs ELISAs were needed and became only available over the years. Bar-Or et al. performed a comprehensive analysis of transcriptional expression of 23 MMPs by quantitative PCR in monocytes as well as in B and T cells from healthy controls and MS patients [<xref ref-type="bibr" rid="CR201">201</xref>]. Each of these cell types had their specific pattern of enzymes across the involved members of the MMP family. A specific increase of MMP-2 and -14, and of TIMP-2 in monocytes of MS patients was observed. Kouwenhoven et al. found that mRNA levels of MMP-1, -3, -7, -9 and of TIMP-1 in monocytes were elevated in MS, while those of MMP-14 did not differ, as compared to controls [<xref ref-type="bibr" rid="CR202">202</xref>]. These studies underline that molecular mechanisms of tissue degradation are not restricted to only MMP-9, but result from an interplay of many MMPs from many cellular sources. Nevertheless, while results from different investigators show a high degree of congruency, there are discrepancies that may reflect the heterogeneity of characteristics of MS patients investigated.</p><p id="Par71">Initially, MMPs were considered &#x02018;good for physiologic growth, but bad in MS&#x02019;. As shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, this overly simplistic concept has been revised in recent years, as the effects of MMPs on ECM metabolism are not only of destructive character, but includes as well reparative functions, depending on the phase of MS. MMP-9 is involved in oligodendrocyte regrowth [<xref ref-type="bibr" rid="CR203">203</xref>], while MMP-7 cleaves remyelination-impairing fibronectin to allow remyelination, and the authors speculate that a too low MMP-7 level contributes to the persistence of demyelination in chronic MS lesions and prevents oligodendrocyte maturation [<xref ref-type="bibr" rid="CR204">204</xref>]. A further function of MMPs for synaptogenesis has been recognized [<xref ref-type="bibr" rid="CR205">205</xref>, <xref ref-type="bibr" rid="CR206">206</xref>]. These findings are relevant for the concept how MMP inhibition could be used as therapeutic approach in MS. When leucocyte extravasation into lesions has ceased after re-establishment of the BBB, microglia are major sources of MMPs in the CNS. However, it is not known whether or when microglial activation is contributing to active progression in MS, or is actually a beneficial reaction to preserve tissue integrity. Hence, it is not clear at which time point and for how long therapeutic MMP inhibition could be beneficial in MS.</p><sec id="Sec23"><title>MMP inhibitors as treatment options for MS</title><p id="Par72">Based on the evidence concerning the role of MMPs in BBB opening and lesion formation, MMP inhibitors (MMPIs) were thought to be an ideal class of compounds for MS therapy in the late 1990s. The development of specific MMPIs for oncology was followed with great interest by the neurology field. In vitro models of metastasis showed dramatic reduction of dissemination and growth of tumor cells, which were thought to be transferable to suppression of BBB transmigration of blood-derived leukocytes in MS. This was bolstered by the observation that current therapies such as IFN&#x003b2;, or later natalizumab [<xref ref-type="bibr" rid="CR207">207</xref>] downregulate MMPs as part of their mode of action. The hypothesis that the therapeutic effect of IFN&#x003b2; may be mediated via its suppressive effect on MMP-9 expression in T cells was further corroborated by a reduction of their migration across an artificial BBB [<xref ref-type="bibr" rid="CR208">208</xref>, <xref ref-type="bibr" rid="CR209">209</xref>].</p><p id="Par73">A number of hydroxamic acid inhibitor type compounds, which inactivate the enzymatic activity of MMPs by binding to the catalytic zinc of MMPs, have led to disease severity attenuation in EAE [<xref ref-type="bibr" rid="CR210">210</xref>&#x02013;<xref ref-type="bibr" rid="CR212">212</xref>]. Similarly, such compounds reduced the capacity of T cells to migrate across an in vitro BBB model [<xref ref-type="bibr" rid="CR213">213</xref>]. However, for several reasons clinical studies have never started. In oncology, the initially promising preclinical results with MMPIs were not confirmed in clinical trials. The same was the case in rheumatoid arthritis. Additionally, depending on their enzymatic target profile, adverse events and specific signs of toxicity were recognized during chronic dosing, which precluded the intended long-term use as maintenance therapy in MS (for review see [<xref ref-type="bibr" rid="CR214">214</xref>]). Evidence for the role of MMPs in tissue repair in subacute and stable phases of the disease suggests that long-term MMP inhibition could have detrimental effects. The intent to overcome this by targeting only &#x02018;bad&#x02019; MMPs via hyper-selective substrate profiles fell short on the basis that tissue destruction and repair can be mediated by the very same MMPs (e.g., MMP-7 and -9) [<xref ref-type="bibr" rid="CR204">204</xref>], depending on the acuity of disease at a given time point.</p><p id="Par74">There is, however, one example of translation of the knowledge on the role of MMPs in MS. Minocycline, a tetracycline antibiotic that exerts broad-spectrum inhibition of MMPs, demonstrated in two phase 2 studies in MS efficacy in reducing gadolinium-enhancing lesions [<xref ref-type="bibr" rid="CR215">215</xref>, <xref ref-type="bibr" rid="CR216">216</xref>], which encouraged the study group to execute a phase 3 clinical trial [<xref ref-type="bibr" rid="CR217">217</xref>] with 142 patients with a first MS attack. Clinical and MRI findings suggested that minocycline in comparison to placebo reduced the risk for patients after a first attack to reach the criteria for formal MS diagnosis within 6&#x000a0;months by 28% (<italic>p</italic>&#x02009;=&#x02009;0.006). The site of primary action of minocycline is likely in the &#x02018;periphery&#x02019;, i.e., the immune system outside the CNS, while it is not known which MMP&#x02019;s inhibition is responsible for the clinical effect. Another potential mode of action apart from direct inhibition of enzymatic activity of several MMPs is interference with their activation. EMMPRIN (extracellular matrix metalloproteinase inducer, CD147) is a membrane glycoprotein of the immunoglobulin superfamily whose levels are reduced in T cells by minocycline [<xref ref-type="bibr" rid="CR218">218</xref>]. Thus, minocycline treatment likely reduces the activity and secondarily the release and production of MMPs resulting in diminished leukocyte extravasation of leukocytes into the CNS. The Canadian study group that has run all minocycline trials in MS so far is preparing currently for another trial (Yong VW, personal communication).</p><p id="Par75">Severity and frequency of relapses are important determinants for the long-term outcome of MS. Steroids are the current standard for intervention therapy to attenuate acute exacerbations in MS; however, their effect on the disability development is very limited. More powerful compounds for this situation represent a high unmet medical need. The effect of hydroxamic acid type MMPIs in EAE is strong pre-clinical evidence for their use in acute exacerbations in MS. Broad-spectrum MMPIs are the obvious drug candidates here, given the array of MMPs upregulated in this condition, as they have been shown to be free of side effects for a dosing period of several days [<xref ref-type="bibr" rid="CR219">219</xref>]. Despite Health Authorities have defined the development path for the development of compounds for relapse therapy [<xref ref-type="bibr" rid="CR220">220</xref>], the pharmaceutical industry has so far not engaged in such development activities. However, this may be an opportunity for a &#x02018;second life&#x02019; for this class of candidate drugs.</p></sec></sec><sec id="Sec24"><title>Conclusion</title><p id="Par76">Metalloproteinases are mediators of neuroinflammatory processes upon neuroinfections and in MS. During these neuroinflammatory diseases, metalloproteinases regulate BBB breakdown, neutrophil infiltration and cytokine signaling. Metalloproteinase inhibitors have experimentally been shown to decrease neuroinflammation and brain damage in diseases with excessive neuroinflammation as a common denominator, thereby improving the outcome of such diseases. Nevertheless, timing of metalloproteinase inhibition appears to be critical to effectively downmodulate the cascade of pathophysiological processes leading to brain damage during PM. On the other hand, metalloproteinases are also mediators of neuroregeneration and synaptogenesis, processes that are therapeutically not intended to be inhibited. As this critical role of metalloproteinases in neuronal repair mechanisms and regeneration was only lately recognized, the original idea of chronic MMP inhibition needs to be conceptually revised. Recently accumulated research urges for a second chance of MMPIs, which&#x02014;when correctly applied and dosed&#x02014;harbor the potential to improve many different neuroinflammatory diseases.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ADAM</term><def><p id="Par2">A disintegrin and metalloproteinase</p></def></def-item><def-item><term>AJ</term><def><p id="Par3">Adherens junction</p></def></def-item><def-item><term>BBB</term><def><p id="Par4">Blood&#x02013;brain barrier</p></def></def-item><def-item><term>CNS</term><def><p id="Par5">Central nervous system</p></def></def-item><def-item><term>CSF</term><def><p id="Par6">Cerebrospinal fluid</p></def></def-item><def-item><term>EAE</term><def><p id="Par7">Experimental autoimmune encephalitis</p></def></def-item><def-item><term>EBV</term><def><p id="Par8">Epstein&#x02013;Barr virus</p></def></def-item><def-item><term>ECM</term><def><p id="Par9">Extracellular matrix</p></def></def-item><def-item><term>HSE</term><def><p id="Par10">Herpes-simplex virus</p></def></def-item><def-item><term>JEV</term><def><p id="Par11">Japanese encephalitis virus</p></def></def-item><def-item><term>MAV-1</term><def><p id="Par12">Mouse adenovirus type-1</p></def></def-item><def-item><term>MBP</term><def><p id="Par13">Myelin basic protein</p></def></def-item><def-item><term>MMP</term><def><p id="Par14">Matrix metalloproteinase</p></def></def-item><def-item><term>MMPI</term><def><p id="Par15">MMP inhibitor</p></def></def-item><def-item><term>MS</term><def><p id="Par16">Multiple sclerosis</p></def></def-item><def-item><term>PM</term><def><p id="Par17">Pneumococcal meningitis</p></def></def-item><def-item><term>PPMS</term><def><p id="Par18">Primary progressive MS</p></def></def-item><def-item><term>ROS</term><def><p id="Par19">Reactive oxygen species</p></def></def-item><def-item><term>RRMS</term><def><p id="Par20">Relapsing&#x02013;remitting MS</p></def></def-item><def-item><term>SPMS</term><def><p id="Par21">Secondary progressive MS</p></def></def-item><def-item><term>TACE</term><def><p id="Par22">TNF-&#x003b1;-converting enzyme</p></def></def-item><def-item><term>TBM</term><def><p id="Par23">Tuberculous meningitis</p></def></def-item><def-item><term>TIMP</term><def><p id="Par24">Tissue inhibitor of metalloproteinase</p></def></def-item><def-item><term>TJ</term><def><p id="Par25">Tight junction</p></def></def-item><def-item><term>WNV</term><def><p id="Par26">West Nile virus</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Daria Baumgartner for her excellent help in designing the summary figure. This work was supported by a grant from the Swiss National Science Foundation (Grant 310030-162583).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yong</surname><given-names>VW</given-names></name></person-group><article-title>Metalloproteinases: mediators of pathology and regeneration in the CNS</article-title><source>Nat Rev Neurosci</source><year>2005</year><volume>6</volume><fpage>931</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1038/nrn1807</pub-id><?supplied-pmid 16288297?><pub-id pub-id-type="pmid">16288297</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sternlicht</surname><given-names>MD</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>How matrix metalloproteinases regulate cell behavior</article-title><source>Annu Rev Cell Dev Biol</source><year>2001</year><volume>17</volume><fpage>463</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.17.1.463</pub-id><?supplied-pmid 11687497?><pub-id pub-id-type="pmid">11687497</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mott</surname><given-names>JD</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Regulation of matrix biology by matrix metalloproteinases</article-title><source>Curr Opin Cell Biol</source><year>2004</year><volume>16</volume><fpage>558</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2004.07.010</pub-id><?supplied-pmid 15363807?><pub-id pub-id-type="pmid">15363807</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCawley</surname><given-names>LJ</given-names></name><name><surname>Matrisian</surname><given-names>LM</given-names></name></person-group><article-title>Matrix metalloproteinases: they&#x02019;re not just for matrix anymore!</article-title><source>Curr Opin Cell Biol</source><year>2001</year><volume>13</volume><fpage>534</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/S0955-0674(00)00248-9</pub-id><pub-id pub-id-type="pmid">11544020</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parks</surname><given-names>WC</given-names></name><name><surname>Wilson</surname><given-names>CL</given-names></name><name><surname>L&#x000f3;pez-Boado</surname><given-names>YS</given-names></name></person-group><article-title>Matrix metalloproteinases as modulators of inflammation and innate immunity</article-title><source>Nat Rev Immunol</source><year>2004</year><volume>4</volume><fpage>617</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1038/nri1418</pub-id><?supplied-pmid 15286728?><pub-id pub-id-type="pmid">15286728</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>JM</given-names></name></person-group><article-title>ADAMs: modulators of cell-cell and cell-matrix interactions</article-title><source>Curr Opin Cell Biol</source><year>2003</year><volume>15</volume><fpage>598</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2003.08.001</pub-id><pub-id pub-id-type="pmid">14519395</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yong</surname><given-names>VW</given-names></name><name><surname>Power</surname><given-names>C</given-names></name><name><surname>Forsyth</surname><given-names>P</given-names></name><name><surname>Edwards</surname><given-names>DR</given-names></name></person-group><article-title>Metalloproteinases in biology and pathology of the nervous system</article-title><source>Nat Rev Neurosci</source><year>2001</year><volume>2</volume><fpage>502</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/35081571</pub-id><?supplied-pmid 11433375?><pub-id pub-id-type="pmid">11433375</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overall</surname><given-names>CM</given-names></name><name><surname>L&#x000f3;pez-Ot&#x000ed;n</surname><given-names>C</given-names></name></person-group><article-title>Strategies for MMP inhibition in cancer: innovations for the post-trial era</article-title><source>Nat Rev Cancer</source><year>2002</year><volume>2</volume><fpage>657</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1038/nrc884</pub-id><?supplied-pmid 12209155?><pub-id pub-id-type="pmid">12209155</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Wart</surname><given-names>HE</given-names></name><name><surname>Birkedal-Hansen</surname><given-names>H</given-names></name></person-group><article-title>The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family</article-title><source>Proc Natl Acad Sci USA</source><year>1990</year><volume>87</volume><fpage>5578</fpage><lpage>5582</lpage><pub-id pub-id-type="doi">10.1073/pnas.87.14.5578</pub-id><pub-id pub-id-type="pmid">2164689</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>SJ</given-names></name><name><surname>Peppin</surname><given-names>G</given-names></name><name><surname>Ortiz</surname><given-names>X</given-names></name><etal/></person-group><article-title>Oxidative autoactivation of latent collagenase by human neutrophils</article-title><source>Science</source><year>1985</year><volume>227</volume><fpage>747</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1126/science.2982211</pub-id><pub-id pub-id-type="pmid">2982211</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peppin</surname><given-names>GJ</given-names></name><name><surname>Weiss</surname><given-names>SJ</given-names></name></person-group><article-title>Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils</article-title><source>Proc Natl Acad Sci USA</source><year>1986</year><volume>83</volume><fpage>4322</fpage><lpage>4326</lpage><pub-id pub-id-type="doi">10.1073/pnas.83.12.4322</pub-id><pub-id pub-id-type="pmid">3012563</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Kassim</surname><given-names>SY</given-names></name><name><surname>Parks</surname><given-names>WC</given-names></name><name><surname>Heinecke</surname><given-names>JW</given-names></name></person-group><article-title>Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>41279</fpage><lpage>41287</lpage><pub-id pub-id-type="doi">10.1074/jbc.M106958200</pub-id><?supplied-pmid 11533038?><pub-id pub-id-type="pmid">11533038</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visse</surname><given-names>R</given-names></name><name><surname>Nagase</surname><given-names>H</given-names></name></person-group><article-title>Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry</article-title><source>Circ Res</source><year>2003</year><volume>92</volume><fpage>827</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000070112.80711.3D</pub-id><?supplied-pmid 12730128?><pub-id pub-id-type="pmid">12730128</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>G</given-names></name><name><surname>Kn&#x000e4;uper</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>M-H</given-names></name><etal/></person-group><article-title>Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail</article-title><source>Biochem Soc Symp</source><year>2003</year><volume>70</volume><fpage>65</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1042/bss0700065</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khokha</surname><given-names>R</given-names></name><name><surname>Murthy</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name></person-group><article-title>Metalloproteinases and their natural inhibitors in inflammation and immunity</article-title><source>Nat Rev Immunol</source><year>2013</year><volume>13</volume><fpage>649</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/nri3499</pub-id><?supplied-pmid 23969736?><pub-id pub-id-type="pmid">23969736</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>GA</given-names></name><name><surname>Mun-Bryce</surname><given-names>S</given-names></name><name><surname>Wesley</surname><given-names>M</given-names></name><name><surname>Kornfeld</surname><given-names>M</given-names></name></person-group><article-title>Collagenase-induced intracerebral hemorrhage in rats</article-title><source>Stroke</source><year>1990</year><volume>21</volume><fpage>801</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1161/01.STR.21.5.801</pub-id><pub-id pub-id-type="pmid">2160142</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>GA</given-names></name><name><surname>Kornfeld</surname><given-names>M</given-names></name><name><surname>Estrada</surname><given-names>E</given-names></name><etal/></person-group><article-title>TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase</article-title><source>Brain Res</source><year>1992</year><volume>576</volume><fpage>203</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(92)90681-X</pub-id><?supplied-pmid 1381261?><pub-id pub-id-type="pmid">1381261</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baranger</surname><given-names>K</given-names></name><name><surname>Rivera</surname><given-names>S</given-names></name><name><surname>Liechti</surname><given-names>FD</given-names></name><etal/></person-group><article-title>Endogenous and synthetic MMP inhibitors in CNS physiopathology</article-title><source>Prog Brain Res</source><year>2014</year><volume>214</volume><fpage>313</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-63486-3.00014-1</pub-id><pub-id pub-id-type="pmid">25410364</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>GA</given-names></name><name><surname>Estrada</surname><given-names>EY</given-names></name><name><surname>Dencoff</surname><given-names>JE</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>WG</given-names></name></person-group><article-title>Tumor necrosis factor-&#x003b1;-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window</article-title><source>Brain Res</source><year>1995</year><volume>703</volume><fpage>151</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(95)01089-0</pub-id><?supplied-pmid 8719627?><pub-id pub-id-type="pmid">8719627</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mun-Bryce</surname><given-names>S</given-names></name><name><surname>Lukes</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>J</given-names></name><etal/></person-group><article-title>Stromelysin-1 and gelatinase A are upregulated before TNF-alpha in LPS-stimulated neuroinflammation</article-title><source>Brain Res</source><year>2002</year><volume>933</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(02)02303-X</pub-id><pub-id pub-id-type="pmid">11929634</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mun-Bryce</surname><given-names>S</given-names></name><name><surname>Rosenberg</surname><given-names>GA</given-names></name></person-group><article-title>Gelatinase B modulates selective opening of the blood-brain barrier during inflammation</article-title><source>Am J Physiol</source><year>1998</year><volume>274</volume><fpage>R1203</fpage><lpage>R1211</lpage><?supplied-pmid 9644031?><pub-id pub-id-type="pmid">9644031</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakhan</surname><given-names>SE</given-names></name><name><surname>Kirchgessner</surname><given-names>A</given-names></name><name><surname>Tepper</surname><given-names>D</given-names></name><name><surname>Leonard</surname><given-names>A</given-names></name></person-group><article-title>Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke</article-title><source>Front Neurol</source><year>2013</year><volume>4</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.3389/fneur.2013.00032</pub-id><?supplied-pmid 23565108?><pub-id pub-id-type="pmid">23565108</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sellner</surname><given-names>J</given-names></name><name><surname>Leib</surname><given-names>SL</given-names></name></person-group><article-title>In bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV degradation</article-title><source>Neurobiol Dis</source><year>2006</year><volume>21</volume><fpage>647</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2005.09.007</pub-id><?supplied-pmid 16257222?><pub-id pub-id-type="pmid">16257222</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>GA</given-names></name><name><surname>Estrada</surname><given-names>EY</given-names></name><name><surname>Dencoff</surname><given-names>JE</given-names></name></person-group><article-title>Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain</article-title><source>Stroke</source><year>1998</year><volume>29</volume><fpage>2189</fpage><lpage>2195</lpage><pub-id pub-id-type="doi">10.1161/01.STR.29.10.2189</pub-id><pub-id pub-id-type="pmid">9756602</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Estrada</surname><given-names>EY</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat</article-title><source>J Cereb Blood Flow Metab</source><year>2007</year><volume>27</volume><fpage>697</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600375</pub-id><?supplied-pmid 16850029?><pub-id pub-id-type="pmid">16850029</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Ohashi</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Disruptions of occludin and claudin-5 in brain endothelial cells in vitro and in brains of mice with acute liver failure</article-title><source>Hepatology</source><year>2009</year><volume>50</volume><fpage>1914</fpage><lpage>1923</lpage><pub-id pub-id-type="doi">10.1002/hep.23203</pub-id><?supplied-pmid 19821483?><pub-id pub-id-type="pmid">19821483</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McColl</surname><given-names>BW</given-names></name><name><surname>Rothwell</surname><given-names>NJ</given-names></name><name><surname>Allan</surname><given-names>SM</given-names></name></person-group><article-title>Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice</article-title><source>J Neurosci</source><year>2008</year><volume>28</volume><fpage>9451</fpage><lpage>9462</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2674-08.2008</pub-id><?supplied-pmid 18799677?><pub-id pub-id-type="pmid">18799677</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adibhatla</surname><given-names>RM</given-names></name><name><surname>Hatcher</surname><given-names>JF</given-names></name></person-group><article-title>Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies</article-title><source>CNS Neurol Disord Drug Targets</source><year>2008</year><volume>7</volume><fpage>243</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.2174/187152708784936608</pub-id><pub-id pub-id-type="pmid">18673209</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gidday</surname><given-names>JM</given-names></name><name><surname>Gasche</surname><given-names>YG</given-names></name><name><surname>Copin</surname><given-names>J-C</given-names></name><etal/></person-group><article-title>Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia</article-title><source>Am J Physiol Circ Physiol</source><year>2005</year><volume>289</volume><fpage>H558</fpage><lpage>H568</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.01275.2004</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group><article-title>Inflammatory mechanisms in ischemic stroke: role of inflammatory cells</article-title><source>J Leukoc Biol</source><year>2010</year><volume>87</volume><fpage>779</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1189/jlb.1109766</pub-id><?supplied-pmid 20130219?><pub-id pub-id-type="pmid">20130219</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Justicia</surname><given-names>C</given-names></name><name><surname>Pan&#x000e9;s</surname><given-names>J</given-names></name><name><surname>Sol&#x000e9;</surname><given-names>S</given-names></name><etal/></person-group><article-title>neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats</article-title><source>J Cereb Blood Flow Metab</source><year>2003</year><volume>23</volume><fpage>1430</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1097/01.WCB.0000090680.07515.C8</pub-id><?supplied-pmid 14663338?><pub-id pub-id-type="pmid">14663338</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meli</surname><given-names>DN</given-names></name><name><surname>Christen</surname><given-names>S</given-names></name><name><surname>Leib</surname><given-names>SL</given-names></name></person-group><article-title>Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway</article-title><source>J Infect Dis</source><year>2003</year><volume>187</volume><fpage>1411</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.1086/374644</pub-id><?supplied-pmid 12717622?><pub-id pub-id-type="pmid">12717622</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opdenakker</surname><given-names>G</given-names></name><name><surname>Van den Steen</surname><given-names>PE</given-names></name><name><surname>Van Damme</surname><given-names>J</given-names></name></person-group><article-title>Gelatinase B: a tuner and amplifier of immune functions</article-title><source>Trends Immunol</source><year>2001</year><volume>22</volume><fpage>571</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1016/S1471-4906(01)02023-3</pub-id><pub-id pub-id-type="pmid">11574282</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masure</surname><given-names>S</given-names></name><name><surname>Proost</surname><given-names>P</given-names></name><name><surname>Van Damme</surname><given-names>J</given-names></name><name><surname>Opdenakker</surname><given-names>G</given-names></name></person-group><article-title>Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8</article-title><source>Eur J Biochem</source><year>1991</year><volume>198</volume><fpage>391</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1991.tb16027.x</pub-id><pub-id pub-id-type="pmid">1645657</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leppert</surname><given-names>D</given-names></name><name><surname>Leib</surname><given-names>SL</given-names></name><name><surname>Grygar</surname><given-names>C</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae</article-title><source>Clin Infect Dis</source><year>2000</year><volume>31</volume><fpage>80</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1086/313922</pub-id><?supplied-pmid 10913401?><pub-id pub-id-type="pmid">10913401</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>T</given-names></name><name><surname>Bischoff</surname><given-names>R</given-names></name></person-group><article-title>Physiology and pathophysiology of matrix metalloproteases</article-title><source>Amino Acids</source><year>2011</year><volume>41</volume><fpage>271</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1007/s00726-010-0689-x</pub-id><?supplied-pmid 20640864?><pub-id pub-id-type="pmid">20640864</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurney</surname><given-names>KJ</given-names></name><name><surname>Estrada</surname><given-names>EY</given-names></name><name><surname>Rosenberg</surname><given-names>GA</given-names></name></person-group><article-title>Blood&#x02013;brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation</article-title><source>Neurobiol Dis</source><year>2006</year><volume>23</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2006.02.006</pub-id><?supplied-pmid 16624562?><pub-id pub-id-type="pmid">16624562</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><etal/></person-group><article-title>The expression of matrix metalloproteinase-13 is increased in vessels with blood&#x02013;brain barrier impairment in a stroke-prone hypertensive model</article-title><source>Hypertens Res</source><year>2009</year><volume>32</volume><fpage>332</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/hr.2009.26</pub-id><?supplied-pmid 19300451?><pub-id pub-id-type="pmid">19300451</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuadrado</surname><given-names>E</given-names></name><name><surname>Rosell</surname><given-names>A</given-names></name><name><surname>Penalba</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study</article-title><source>J Proteome Res</source><year>2009</year><volume>8</volume><fpage>3191</fpage><lpage>3197</lpage><pub-id pub-id-type="doi">10.1021/pr801012x</pub-id><?supplied-pmid 19317417?><pub-id pub-id-type="pmid">19317417</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuadrado</surname><given-names>E</given-names></name><name><surname>Rosell</surname><given-names>A</given-names></name><name><surname>Borrell-Pag&#x000e8;s</surname><given-names>M</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia</article-title><source>J Cereb Blood Flow Metab</source><year>2009</year><volume>29</volume><fpage>398</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2008.130</pub-id><?supplied-pmid 18985055?><pub-id pub-id-type="pmid">18985055</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieseier</surname><given-names>BC</given-names></name><name><surname>Paul</surname><given-names>R</given-names></name><name><surname>Koedel</surname><given-names>U</given-names></name><etal/></person-group><article-title>Differential expression of matrix metalloproteinases in bacterial meningitis</article-title><source>Brain</source><year>1999</year><volume>122</volume><issue>Pt 8</issue><fpage>1579</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.1093/brain/122.8.1579</pub-id><pub-id pub-id-type="pmid">10430840</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>D</given-names></name><name><surname>Arima</surname><given-names>M</given-names></name><name><surname>Takubo</surname><given-names>K</given-names></name><etal/></person-group><article-title>ADAM12 and ADAM17 are essential molecules for hypoxia-induced impairment of neural vascular barrier function</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>12796</fpage><pub-id pub-id-type="doi">10.1038/srep12796</pub-id><?supplied-pmid 26242473?><pub-id pub-id-type="pmid">26242473</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoshima</surname><given-names>I</given-names></name><name><surname>Inoshima</surname><given-names>N</given-names></name><name><surname>Wilke</surname><given-names>GA</given-names></name><etal/></person-group><article-title>A <italic>Staphylococcus aureus</italic> pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice</article-title><source>Nat Med</source><year>2011</year><volume>17</volume><fpage>1310</fpage><lpage>1314</lpage><pub-id pub-id-type="doi">10.1038/nm.2451</pub-id><?supplied-pmid 21926978?><pub-id pub-id-type="pmid">21926978</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponnuchamy</surname><given-names>B</given-names></name><name><surname>Khalil</surname><given-names>RA</given-names></name></person-group><article-title>Role of ADAMs in endothelial cell permeability: cadherin shedding and leukocyte rolling</article-title><source>Circ Res</source><year>2008</year><volume>102</volume><fpage>1139</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.177394</pub-id><?supplied-pmid 18497310?><pub-id pub-id-type="pmid">18497310</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>J</given-names></name><name><surname>Lapiere</surname><given-names>CM</given-names></name></person-group><article-title>Collagenolytic activity in amphibian tissues: a tissue culture assay</article-title><source>Proc Natl Acad Sci USA</source><year>1962</year><volume>48</volume><fpage>1014</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1073/pnas.48.6.1014</pub-id><pub-id pub-id-type="pmid">13902219</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Steen</surname><given-names>PE</given-names></name><name><surname>Proost</surname><given-names>P</given-names></name><name><surname>Wuyts</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact</article-title><source>Blood</source><year>2000</year><volume>96</volume><fpage>2673</fpage><lpage>2681</lpage><?supplied-pmid 11023497?><pub-id pub-id-type="pmid">11023497</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McQuibban</surname><given-names>GA</given-names></name><name><surname>Gong</surname><given-names>JH</given-names></name><name><surname>Tam</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3</article-title><source>Science</source><year>2000</year><volume>289</volume><fpage>1202</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1126/science.289.5482.1202</pub-id><pub-id pub-id-type="pmid">10947989</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McQuibban</surname><given-names>GA</given-names></name><name><surname>Gong</surname><given-names>J-H</given-names></name><name><surname>Wong</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>1160</fpage><lpage>1167</lpage><?supplied-pmid 12149192?><pub-id pub-id-type="pmid">12149192</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McQuibban</surname><given-names>GA</given-names></name><name><surname>Butler</surname><given-names>GS</given-names></name><name><surname>Gong</surname><given-names>J-H</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>43503</fpage><lpage>43508</lpage><pub-id pub-id-type="doi">10.1074/jbc.M107736200</pub-id><?supplied-pmid 11571304?><pub-id pub-id-type="pmid">11571304</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>McQuibban</surname><given-names>GA</given-names></name><name><surname>Silva</surname><given-names>C</given-names></name><etal/></person-group><article-title>HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration</article-title><source>Nat Neurosci</source><year>2003</year><volume>6</volume><fpage>1064</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1038/nn1127</pub-id><?supplied-pmid 14502291?><pub-id pub-id-type="pmid">14502291</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Sorokin</surname><given-names>LM</given-names></name></person-group><article-title>In vivo processing of CXCL5 (LIX) by matrix metalloproteinase (MMP)-2 and MMP-9 promotes early neutrophil recruitment in IL-1-induced peritonitis</article-title><source>J Immunol</source><year>2013</year><volume>190</volume><fpage>401</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202286</pub-id><?supplied-pmid 23225890?><pub-id pub-id-type="pmid">23225890</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tester</surname><given-names>AM</given-names></name><name><surname>Cox</surname><given-names>JH</given-names></name><name><surname>Connor</surname><given-names>AR</given-names></name><etal/></person-group><article-title>LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity</article-title><source>PLoS One</source><year>2007</year><volume>2</volume><fpage>e312</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0000312</pub-id><?supplied-pmid 17375198?><pub-id pub-id-type="pmid">17375198</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afonso</surname><given-names>PV</given-names></name><name><surname>McCann</surname><given-names>CP</given-names></name><name><surname>Kapnick</surname><given-names>SM</given-names></name><name><surname>Parent</surname><given-names>CA</given-names></name></person-group><article-title>Discoidin domain receptor 2 regulates neutrophil chemotaxis in 3D collagen matrices</article-title><source>Blood</source><year>2013</year><volume>121</volume><fpage>1644</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-08-451575</pub-id><?supplied-pmid 23233663?><pub-id pub-id-type="pmid">23233663</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Den Steen</surname><given-names>PE</given-names></name><name><surname>Wuyts</surname><given-names>A</given-names></name><name><surname>Husson</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities</article-title><source>Eur J Biochem</source><year>2003</year><volume>270</volume><fpage>3739</fpage><lpage>3749</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1033.2003.03760.x</pub-id><pub-id pub-id-type="pmid">12950257</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khandaker</surname><given-names>MH</given-names></name><name><surname>Mitchell</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Metalloproteinases are involved in lipopolysaccharide- and tumor necrosis factor-alpha-mediated regulation of CXCR55 and CXCR55 chemokine receptor expression</article-title><source>Blood</source><year>1999</year><volume>93</volume><fpage>2173</fpage><lpage>2185</lpage><?supplied-pmid 10090924?><pub-id pub-id-type="pmid">10090924</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Park</surname><given-names>PW</given-names></name><name><surname>Wilson</surname><given-names>CL</given-names></name><name><surname>Parks</surname><given-names>WC</given-names></name></person-group><article-title>Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury</article-title><source>Cell</source><year>2002</year><volume>111</volume><fpage>635</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)01079-6</pub-id><pub-id pub-id-type="pmid">12464176</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corry</surname><given-names>DB</given-names></name><name><surname>Rishi</surname><given-names>K</given-names></name><name><surname>Kanellis</surname><given-names>J</given-names></name><etal/></person-group><article-title>Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency</article-title><source>Nat Immunol</source><year>2002</year><volume>3</volume><fpage>347</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1038/ni773</pub-id><?supplied-pmid 11887181?><pub-id pub-id-type="pmid">11887181</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corry</surname><given-names>DB</given-names></name><name><surname>Kiss</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>L-Z</given-names></name><etal/></person-group><article-title>Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines</article-title><source>FASEB J</source><year>2004</year><volume>18</volume><fpage>995</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1096/fj.03-1412fje</pub-id><?supplied-pmid 15059974?><pub-id pub-id-type="pmid">15059974</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornberry</surname><given-names>NA</given-names></name><name><surname>Bull</surname><given-names>HG</given-names></name><name><surname>Calaycay</surname><given-names>JR</given-names></name><etal/></person-group><article-title>A novel heterodimeric cysteine protease is required for interleukin-1&#x003b2;processing in monocytes</article-title><source>Nature</source><year>1992</year><volume>356</volume><fpage>768</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1038/356768a0</pub-id><?supplied-pmid 1574116?><pub-id pub-id-type="pmid">1574116</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostura</surname><given-names>MJ</given-names></name><name><surname>Tocci</surname><given-names>MJ</given-names></name><name><surname>Limjuco</surname><given-names>G</given-names></name><etal/></person-group><article-title>Identification of a monocyte specific pre-interleukin 1 beta convertase activity</article-title><source>Proc Natl Acad Sci USA</source><year>1989</year><volume>86</volume><fpage>5227</fpage><lpage>5231</lpage><pub-id pub-id-type="doi">10.1073/pnas.86.14.5227</pub-id><pub-id pub-id-type="pmid">2787508</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fantuzzi</surname><given-names>G</given-names></name><name><surname>Ku</surname><given-names>G</given-names></name><name><surname>Harding</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Response to local inflammation of IL-1 beta-converting enzyme-deficient mice</article-title><source>J Immunol</source><year>1997</year><volume>158</volume><fpage>1818</fpage><lpage>1824</lpage><?supplied-pmid 9029121?><pub-id pub-id-type="pmid">9029121</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000f6;nbeck</surname><given-names>U</given-names></name><name><surname>Mach</surname><given-names>F</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>3340</fpage><lpage>3346</lpage><?supplied-pmid 9759850?><pub-id pub-id-type="pmid">9759850</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>ML</given-names></name><name><surname>Jin</surname><given-names>S-LC</given-names></name><name><surname>Milla</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-&#x003b1;</article-title><source>Nature</source><year>1997</year><volume>385</volume><fpage>733</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1038/385733a0</pub-id><?supplied-pmid 9034191?><pub-id pub-id-type="pmid">9034191</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>RA</given-names></name><name><surname>Rauch</surname><given-names>CT</given-names></name><name><surname>Kozlosky</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>A metalloproteinase disintegrin that releases tumour-necrosis factor-&#x003b1; from cells</article-title><source>Nature</source><year>1997</year><volume>385</volume><fpage>729</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1038/385729a0</pub-id><?supplied-pmid 9034190?><pub-id pub-id-type="pmid">9034190</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohan</surname><given-names>MJ</given-names></name><name><surname>Seaton</surname><given-names>T</given-names></name><name><surname>Mitchell</surname><given-names>J</given-names></name><etal/></person-group><article-title>The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity</article-title><source>Biochemistry</source><year>2002</year><volume>41</volume><fpage>9462</fpage><lpage>9469</lpage><pub-id pub-id-type="doi">10.1021/bi0260132</pub-id><pub-id pub-id-type="pmid">12135369</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Stamenkovic</surname><given-names>I</given-names></name></person-group><article-title>Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis</article-title><source>Genes Dev</source><year>2000</year><volume>14</volume><fpage>163</fpage><lpage>176</lpage><?supplied-pmid 10652271?><pub-id pub-id-type="pmid">10652271</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karsdal</surname><given-names>MA</given-names></name><name><surname>Larsen</surname><given-names>L</given-names></name><name><surname>Engsig</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-dependent activation of latent transforming growth factor-&#x003b2; controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>44061</fpage><lpage>44067</lpage><pub-id pub-id-type="doi">10.1074/jbc.M207205200</pub-id><?supplied-pmid 12226090?><pub-id pub-id-type="pmid">12226090</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Dean</surname><given-names>DD</given-names></name><name><surname>Gomez</surname><given-names>R</given-names></name><etal/></person-group><article-title>The first stage of transforming growth factor &#x003b2;1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3)</article-title><source>Calcif Tissue Int</source><year>2002</year><volume>70</volume><fpage>54</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/s002230010032</pub-id><?supplied-pmid 11907708?><pub-id pub-id-type="pmid">11907708</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munger</surname><given-names>JS</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Kawakatsu</surname><given-names>H</given-names></name><etal/></person-group><article-title>The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis</article-title><source>Cell</source><year>1999</year><volume>96</volume><fpage>319</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80545-0</pub-id><pub-id pub-id-type="pmid">10025398</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shull</surname><given-names>MM</given-names></name><name><surname>Ormsby</surname><given-names>I</given-names></name><name><surname>Kier</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Targeted disruption of the mouse transforming growth factor-&#x003b2;1 gene results in multifocal inflammatory disease</article-title><source>Nature</source><year>1992</year><volume>359</volume><fpage>693</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1038/359693a0</pub-id><?supplied-pmid 1436033?><pub-id pub-id-type="pmid">1436033</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gearing</surname><given-names>AJH</given-names></name><name><surname>Beckett</surname><given-names>P</given-names></name><name><surname>Christodoulou</surname><given-names>M</given-names></name><etal/></person-group><article-title>Processing of tumour necrosis factor-&#x003b1; precursor by metalloproteinases</article-title><source>Nature</source><year>1994</year><volume>370</volume><fpage>555</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1038/370555a0</pub-id><?supplied-pmid 8052310?><pub-id pub-id-type="pmid">8052310</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grell</surname><given-names>M</given-names></name><name><surname>Douni</surname><given-names>E</given-names></name><name><surname>Wajant</surname><given-names>H</given-names></name><etal/></person-group><article-title>The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80&#x000a0;kDa tumor necrosis factor receptor</article-title><source>Cell</source><year>1995</year><volume>83</volume><fpage>793</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90192-2</pub-id><pub-id pub-id-type="pmid">8521496</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>JH</given-names></name><name><surname>Herrera</surname><given-names>AH</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Walcheck</surname><given-names>B</given-names></name></person-group><article-title>Role of ADAM17 in the ectodomain shedding of TNF-and its receptors by neutrophils and macrophages</article-title><source>J Leukoc Biol</source><year>2007</year><volume>82</volume><fpage>173</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1189/jlb.0307193</pub-id><?supplied-pmid 17510296?><pub-id pub-id-type="pmid">17510296</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peschon</surname><given-names>JJ</given-names></name><name><surname>Slack</surname><given-names>JL</given-names></name><name><surname>Reddy</surname><given-names>P</given-names></name><etal/></person-group><article-title>An essential role for ectodomain shedding in mammalian development</article-title><source>Science</source><year>1998</year><volume>282</volume><fpage>1281</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1126/science.282.5392.1281</pub-id><pub-id pub-id-type="pmid">9812885</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horiuchi</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Miyamoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><fpage>2686</fpage><lpage>2689</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.5.2686</pub-id><pub-id pub-id-type="pmid">17709479</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smookler</surname><given-names>DS</given-names></name><name><surname>Mohammed</surname><given-names>FF</given-names></name><name><surname>Kassiri</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation</article-title><source>J Immunol</source><year>2006</year><volume>176</volume><fpage>721</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.2.721</pub-id><pub-id pub-id-type="pmid">16393953</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garbers</surname><given-names>C</given-names></name><name><surname>J&#x000e4;nner</surname><given-names>N</given-names></name><name><surname>Chalaris</surname><given-names>A</given-names></name><etal/></person-group><article-title>Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>14804</fpage><lpage>14811</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.229393</pub-id><?supplied-pmid 21454673?><pub-id pub-id-type="pmid">21454673</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briso</surname><given-names>EM</given-names></name><name><surname>Dienz</surname><given-names>O</given-names></name><name><surname>Rincon</surname><given-names>M</given-names></name></person-group><article-title>Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells</article-title><source>J Immunol</source><year>2008</year><volume>180</volume><fpage>7102</fpage><lpage>7106</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.11.7102</pub-id><pub-id pub-id-type="pmid">18490707</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smalley</surname><given-names>DM</given-names></name><name><surname>Ley</surname><given-names>K</given-names></name></person-group><article-title>L-selectin: mechanisms and physiological significance of ectodomain cleavage</article-title><source>J Cell Mol Med</source><year>2005</year><volume>9</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2005.tb00354.x</pub-id><pub-id pub-id-type="pmid">15963248</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Zarbock</surname><given-names>A</given-names></name><name><surname>Gomez</surname><given-names>I</given-names></name><etal/></person-group><article-title>Adam17-dependent shedding limits early neutrophil influx but does not alter early monocyte recruitment to inflammatory sites</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>786</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-11-321406</pub-id><?supplied-pmid 21628404?><pub-id pub-id-type="pmid">21628404</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>C</given-names></name><name><surname>Hosseinkhani</surname><given-names>MR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>ADAM17 activation in circulating neutrophils following bacterial challenge impairs their recruitment</article-title><source>J Leukoc Biol</source><year>2012</year><volume>92</volume><fpage>667</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1189/jlb.0312112</pub-id><?supplied-pmid 22623356?><pub-id pub-id-type="pmid">22623356</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahin</surname><given-names>U</given-names></name><name><surname>Weskamp</surname><given-names>G</given-names></name><name><surname>Kelly</surname><given-names>K</given-names></name><etal/></person-group><article-title>Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands</article-title><source>J Cell Biol</source><year>2004</year><volume>164</volume><fpage>769</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1083/jcb.200307137</pub-id><?supplied-pmid 14993236?><pub-id pub-id-type="pmid">14993236</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalaris</surname><given-names>A</given-names></name><name><surname>Adam</surname><given-names>N</given-names></name><name><surname>Sina</surname><given-names>C</given-names></name><etal/></person-group><article-title>Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice</article-title><source>J Exp Med</source><year>2010</year><volume>207</volume><fpage>1617</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.1084/jem.20092366</pub-id><?supplied-pmid 20603312?><pub-id pub-id-type="pmid">20603312</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brou</surname><given-names>C</given-names></name><name><surname>Logeat</surname><given-names>F</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><etal/></person-group><article-title>A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE</article-title><source>Mol Cell</source><year>2000</year><volume>5</volume><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80417-7</pub-id><pub-id pub-id-type="pmid">10882063</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Tetering</surname><given-names>G</given-names></name><name><surname>van Diest</surname><given-names>P</given-names></name><name><surname>Verlaan</surname><given-names>I</given-names></name><etal/></person-group><article-title>Metalloprotease ADAM10 is required for Notch1 site 2 cleavage</article-title><source>J Biol Chem</source><year>2009</year><volume>284</volume><fpage>31018</fpage><lpage>31027</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.006775</pub-id><?supplied-pmid 19726682?><pub-id pub-id-type="pmid">19726682</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murthy</surname><given-names>A</given-names></name><name><surname>Shao</surname><given-names>YW</given-names></name><name><surname>Narala</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis</article-title><source>Immunity</source><year>2012</year><volume>36</volume><fpage>105</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.01.005</pub-id><?supplied-pmid 22284418?><pub-id pub-id-type="pmid">22284418</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Newton</surname><given-names>R</given-names></name><etal/></person-group><article-title>ADAM17 cleaves CD16b (Fc&#x003b3;RIIIb) in human neutrophils</article-title><source>Biochim Biophys Acta</source><year>2013</year><volume>1833</volume><fpage>680</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2012.11.027</pub-id><?supplied-pmid 23228566?><pub-id pub-id-type="pmid">23228566</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moncada-Pazos</surname><given-names>A</given-names></name><name><surname>Obaya</surname><given-names>AJ</given-names></name><name><surname>Llamazares</surname><given-names>M</given-names></name><etal/></person-group><article-title>ADAMTS-12 metalloprotease is necessary for normal inflammatory response</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>39554</fpage><lpage>39563</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.408625</pub-id><?supplied-pmid 23019333?><pub-id pub-id-type="pmid">23019333</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>M-E</given-names></name><name><surname>Stevens</surname><given-names>B</given-names></name><name><surname>Sierra</surname><given-names>A</given-names></name><etal/></person-group><article-title>The role of microglia in the healthy brain</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>16064</fpage><lpage>16069</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4158-11.2011</pub-id><?supplied-pmid 22072657?><pub-id pub-id-type="pmid">22072657</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graeber</surname><given-names>MB</given-names></name><name><surname>Streit</surname><given-names>WJ</given-names></name></person-group><article-title>Microglia: biology and pathology</article-title><source>Acta Neuropathol</source><year>2010</year><volume>119</volume><fpage>89</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1007/s00401-009-0622-0</pub-id><?supplied-pmid 20012873?><pub-id pub-id-type="pmid">20012873</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherry</surname><given-names>JD</given-names></name><name><surname>Olschowka</surname><given-names>JA</given-names></name><name><surname>O&#x02019;Banion</surname><given-names>M</given-names></name></person-group><article-title>Neuroinflammation and M2 microglia: the good, the bad, and the inflamed</article-title><source>J Neuroinflammation</source><year>2014</year><volume>11</volume><fpage>98</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-11-98</pub-id><?supplied-pmid 24889886?><pub-id pub-id-type="pmid">24889886</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boche</surname><given-names>D</given-names></name><name><surname>Perry</surname><given-names>VH</given-names></name><name><surname>Nicoll</surname><given-names>JAR</given-names></name></person-group><article-title>Review: activation patterns of microglia and their identification in the human brain</article-title><source>Neuropathol Appl Neurobiol</source><year>2013</year><volume>39</volume><fpage>3</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1111/nan.12011</pub-id><?supplied-pmid 23252647?><pub-id pub-id-type="pmid">23252647</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>GA</given-names></name></person-group><article-title>Matrix metalloproteinases in neuroinflammation</article-title><source>Glia</source><year>2002</year><volume>39</volume><fpage>279</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1002/glia.10108</pub-id><?supplied-pmid 12203394?><pub-id pub-id-type="pmid">12203394</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuttall</surname><given-names>RK</given-names></name><name><surname>Silva</surname><given-names>C</given-names></name><name><surname>Hader</surname><given-names>W</given-names></name><etal/></person-group><article-title>Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia</article-title><source>Glia</source><year>2007</year><volume>55</volume><fpage>516</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1002/glia.20478</pub-id><?supplied-pmid 17216595?><pub-id pub-id-type="pmid">17216595</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W-C</given-names></name><name><surname>Sala-Newby</surname><given-names>GB</given-names></name><name><surname>Susana</surname><given-names>A</given-names></name><etal/></person-group><article-title>Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-&#x003ba;B</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e42507</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0042507</pub-id><?supplied-pmid 22880008?><pub-id pub-id-type="pmid">22880008</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>M</given-names></name><name><surname>Ninomiya</surname><given-names>I</given-names></name><name><surname>Hatakeyama</surname><given-names>M</given-names></name><etal/></person-group><article-title>Microglia and monocytes/macrophages polarization reveal novel therapeutic mechanism against stroke</article-title><source>Int J Mol Sci</source><year>2017</year><volume>18</volume><fpage>2135</fpage><pub-id pub-id-type="doi">10.3390/ijms18102135</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>M</given-names></name><name><surname>Miura</surname><given-names>M</given-names></name><name><surname>Toriyabe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Microglia preconditioned by oxygen-glucose deprivation promote functional recovery in ischemic rats</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>42582</fpage><pub-id pub-id-type="doi">10.1038/srep42582</pub-id><?supplied-pmid 28195185?><pub-id pub-id-type="pmid">28195185</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S-R</given-names></name><name><surname>Kim</surname><given-names>H-Y</given-names></name><name><surname>Rogowska</surname><given-names>J</given-names></name><etal/></person-group><article-title>Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><fpage>3491</fpage><lpage>3495</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4085-05.2006</pub-id><?supplied-pmid 16571756?><pub-id pub-id-type="pmid">16571756</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>ZG</given-names></name><name><surname>Zhang</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><fpage>5996</fpage><lpage>6003</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5380-05.2006</pub-id><?supplied-pmid 16738242?><pub-id pub-id-type="pmid">16738242</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B-Q</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>H-Y</given-names></name><etal/></person-group><article-title>Role of matrix metalloproteinases in delayed cortical responses after stroke</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>441</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1038/nm1387</pub-id><?supplied-pmid 16565723?><pub-id pub-id-type="pmid">16565723</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Candelario-Jalil</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Rosenberg</surname><given-names>GA</given-names></name></person-group><article-title>Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia</article-title><source>Neuroscience</source><year>2009</year><volume>158</volume><fpage>983</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.06.025</pub-id><?supplied-pmid 18621108?><pub-id pub-id-type="pmid">18621108</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosell</surname><given-names>A</given-names></name><name><surname>Lo</surname><given-names>E</given-names></name></person-group><article-title>Multiphasic roles for matrix metalloproteinases after stroke</article-title><source>Curr Opin Pharmacol</source><year>2008</year><volume>8</volume><fpage>82</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2007.12.001</pub-id><?supplied-pmid 18226583?><pub-id pub-id-type="pmid">18226583</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sood</surname><given-names>RR</given-names></name><name><surname>Taheri</surname><given-names>S</given-names></name><name><surname>Candelario-Jalil</surname><given-names>E</given-names></name><etal/></person-group><article-title>Early beneficial effect of matrix metalloproteinase inhibition on blood&#x02014;brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain</article-title><source>J Cereb Blood Flow Metab</source><year>2008</year><volume>28</volume><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600534</pub-id><?supplied-pmid 17700631?><pub-id pub-id-type="pmid">17700631</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Agyeman</surname><given-names>P</given-names></name><name><surname>Grandgirard</surname><given-names>D</given-names></name><name><surname>Leib</surname><given-names>SL</given-names></name></person-group><article-title>Neuroinflammation in bacterial meningitis</article-title><source>The blood brain barrier and inflammation</source><year>2017</year><publisher-loc>Cham</publisher-loc><publisher-name>Springer International Publishing</publisher-name><fpage>213</fpage><lpage>252</lpage></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Agyeman</surname><given-names>P</given-names></name><name><surname>Grandgirard</surname><given-names>D</given-names></name><name><surname>Leib</surname><given-names>S</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Scheld</surname><given-names>M</given-names></name><name><surname>Whitley</surname><given-names>RJ</given-names></name><name><surname>Marra</surname><given-names>CM</given-names></name></person-group><article-title>Pathogenesis and pathophysiology of bacterial infections</article-title><source>Infections of the central nervous system</source><year>2014</year><publisher-loc>Philadelphia, PA, USA</publisher-loc><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><fpage>341</fpage><lpage>364</lpage></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Beek</surname><given-names>D</given-names></name><name><surname>Cabellos</surname><given-names>C</given-names></name><name><surname>Dzupova</surname><given-names>O</given-names></name><etal/></person-group><article-title>ESCMID guideline: diagnosis and treatment of acute bacterial meningitis</article-title><source>Clin Microbiol Infect</source><year>2016</year><volume>22</volume><fpage>S37</fpage><lpage>S62</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2016.01.007</pub-id><?supplied-pmid 27062097?><pub-id pub-id-type="pmid">27062097</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koedel</surname><given-names>U</given-names></name><name><surname>Scheld</surname><given-names>WM</given-names></name><name><surname>Pfister</surname><given-names>H-W</given-names></name></person-group><article-title>Pathogenesis and pathophysiology of pneumococcal meningitis</article-title><source>Lancet Infect Dis</source><year>2002</year><volume>2</volume><fpage>721</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(02)00450-4</pub-id><pub-id pub-id-type="pmid">12467688</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edmond</surname><given-names>K</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Korczak</surname><given-names>VS</given-names></name><etal/></person-group><article-title>Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis</article-title><source>Lancet Infect Dis</source><year>2010</year><volume>10</volume><fpage>317</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(10)70048-7</pub-id><?supplied-pmid 20417414?><pub-id pub-id-type="pmid">20417414</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brouwer</surname><given-names>MC</given-names></name><name><surname>Tunkel</surname><given-names>AR</given-names></name><name><surname>van de Beek</surname><given-names>D</given-names></name></person-group><article-title>Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis</article-title><source>Clin Microbiol Rev</source><year>2010</year><volume>23</volume><fpage>467</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1128/CMR.00070-09</pub-id><?supplied-pmid 20610819?><pub-id pub-id-type="pmid">20610819</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wellmer</surname><given-names>A</given-names></name><name><surname>Noeske</surname><given-names>C</given-names></name><name><surname>Gerber</surname><given-names>J</given-names></name><etal/></person-group><article-title>Spatial memory and learning deficits after experimental pneumococcal meningitis in mice</article-title><source>Neurosci Lett</source><year>2000</year><volume>296</volume><fpage>137</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(00)01645-1</pub-id><pub-id pub-id-type="pmid">11109000</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeffler</surname><given-names>JM</given-names></name><name><surname>Ringer</surname><given-names>R</given-names></name><name><surname>Habl&#x000fc;tzel</surname><given-names>M</given-names></name><etal/></person-group><article-title>The free radical scavenger &#x003b1;-phenyl-<italic>tert</italic>-butyl nitrone aggravates hippocampal apoptosis and learning deficits in experimental pneumococcal meningitis</article-title><source>J Infect Dis</source><year>2001</year><volume>183</volume><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1086/317921</pub-id><?supplied-pmid 11110643?><pub-id pub-id-type="pmid">11110643</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nau</surname><given-names>R</given-names></name><name><surname>Br&#x000fc;ck</surname><given-names>W</given-names></name></person-group><article-title>Neuronal injury in bacterial meningitis: mechanisms and implications for therapy</article-title><source>Trends Neurosci</source><year>2002</year><volume>25</volume><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/S0166-2236(00)02024-5</pub-id><pub-id pub-id-type="pmid">11801337</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leib</surname><given-names>SL</given-names></name><name><surname>Heimgartner</surname><given-names>C</given-names></name><name><surname>Bifrare</surname><given-names>Y-D</given-names></name><etal/></person-group><article-title>Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats</article-title><source>Pediatr Res</source><year>2003</year><volume>54</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1203/01.PDR.0000079185.67878.72</pub-id><?supplied-pmid 12788989?><pub-id pub-id-type="pmid">12788989</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nau</surname><given-names>R</given-names></name><name><surname>Soto</surname><given-names>A</given-names></name><name><surname>Bruck</surname><given-names>W</given-names></name></person-group><article-title>Apoptosis of neurons in the dentate gyrus in humans suffering from bacterial meningitis</article-title><source>J Neuropathol Exp Neurol</source><year>1999</year><volume>58</volume><fpage>265</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1097/00005072-199903000-00006</pub-id><?supplied-pmid 10197818?><pub-id pub-id-type="pmid">10197818</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerber</surname><given-names>J</given-names></name><name><surname>Nau</surname><given-names>R</given-names></name></person-group><article-title>Mechanisms of injury in bacterial meningitis</article-title><source>Curr Opin Neurol</source><year>2010</year><volume>23</volume><fpage>312</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1097/WCO.0b013e32833950dd</pub-id><?supplied-pmid 20442574?><pub-id pub-id-type="pmid">20442574</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mook-Kanamori</surname><given-names>BB</given-names></name><name><surname>Geldhoff</surname><given-names>M</given-names></name><name><surname>van der Poll</surname><given-names>T</given-names></name><name><surname>van de Beek</surname><given-names>D</given-names></name></person-group><article-title>Pathogenesis and pathophysiology of pneumococcal meningitis</article-title><source>Clin Microbiol Rev</source><year>2011</year><volume>24</volume><fpage>557</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1128/CMR.00008-11</pub-id><?supplied-pmid 21734248?><pub-id pub-id-type="pmid">21734248</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>SH</given-names></name><name><surname>Braun</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Dual phases of apoptosis in pneumococcal meningitis</article-title><source>J Infect Dis</source><year>2004</year><volume>190</volume><fpage>2039</fpage><lpage>2046</lpage><pub-id pub-id-type="doi">10.1086/425520</pub-id><?supplied-pmid 15529270?><pub-id pub-id-type="pmid">15529270</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gianinazzi</surname><given-names>C</given-names></name><name><surname>Grandgirard</surname><given-names>D</given-names></name><name><surname>Imboden</surname><given-names>H</given-names></name><etal/></person-group><article-title>Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis</article-title><source>Acta Neuropathol</source><year>2003</year><volume>105</volume><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1007/s00401-003-0672-7</pub-id><?supplied-pmid 12677451?><pub-id pub-id-type="pmid">12677451</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iliev</surname><given-names>AI</given-names></name><name><surname>Stringaris</surname><given-names>AK</given-names></name><name><surname>Nau</surname><given-names>R</given-names></name><name><surname>Neumann</surname><given-names>H</given-names></name></person-group><article-title>Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9)</article-title><source>FASEB J</source><year>2003</year><volume>18</volume><fpage>412</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1096/fj.03-0670fje</pub-id><?supplied-pmid 14688201?><pub-id pub-id-type="pmid">14688201</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>CP</given-names></name><name><surname>Cheeran</surname><given-names>MC-J</given-names></name><name><surname>Palmquist</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Microglia are the major cellular source of inducible nitric oxide synthase during experimental herpes encephalitis</article-title><source>J Neurovirol</source><year>2008</year><volume>14</volume><fpage>229</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1080/13550280802093927</pub-id><?supplied-pmid 18569457?><pub-id pub-id-type="pmid">18569457</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perny</surname><given-names>M</given-names></name><name><surname>Solyga</surname><given-names>M</given-names></name><name><surname>Grandgirard</surname><given-names>D</given-names></name><etal/></person-group><article-title><italic>Streptococcus pneumoniae</italic>-induced ototoxicity in organ of Corti explant cultures</article-title><source>Hear Res</source><year>2017</year><volume>350</volume><fpage>100</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.heares.2017.04.012</pub-id><?supplied-pmid 28460251?><pub-id pub-id-type="pmid">28460251</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perny</surname><given-names>M</given-names></name><name><surname>Roccio</surname><given-names>M</given-names></name><name><surname>Grandgirard</surname><given-names>D</given-names></name><etal/></person-group><article-title>The severity of infection determines the localization of damage and extent of sensorineural hearing loss in experimental pneumococcal meningitis</article-title><source>J Neurosci</source><year>2016</year><volume>36</volume><fpage>7740</fpage><lpage>7749</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0554-16.2016</pub-id><?supplied-pmid 27445150?><pub-id pub-id-type="pmid">27445150</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Koedel</surname><given-names>U</given-names></name><name><surname>Pfister</surname><given-names>H-W</given-names></name><name><surname>Kastenbauer</surname><given-names>S</given-names></name></person-group><article-title>Morphological correlates of acute and permanent hearing loss during experimental pneumococcal meningitis</article-title><source>Brain Pathol</source><year>2003</year><volume>13</volume><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2003.tb00012.x</pub-id><?supplied-pmid 12744466?><pub-id pub-id-type="pmid">12744466</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Beek</surname><given-names>D</given-names></name><name><surname>de Gans</surname><given-names>J</given-names></name><name><surname>Spanjaard</surname><given-names>L</given-names></name><etal/></person-group><article-title>Clinical features and prognostic factors in adults with bacterial meningitis</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>1849</fpage><lpage>1859</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa040845</pub-id><?supplied-pmid 15509818?><pub-id pub-id-type="pmid">15509818</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandran</surname><given-names>A</given-names></name><name><surname>Herbert</surname><given-names>H</given-names></name><name><surname>Misurski</surname><given-names>D</given-names></name><name><surname>Santosham</surname><given-names>M</given-names></name></person-group><article-title>Long-term sequelae of childhood bacterial meningitis: an underappreciated problem</article-title><source>Pediatr Infect Dis J</source><year>2011</year><volume>30</volume><fpage>3</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/INF.0b013e3181ef25f7</pub-id><?supplied-pmid 20683377?><pub-id pub-id-type="pmid">20683377</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Furth</surname><given-names>AM</given-names></name><name><surname>Roord</surname><given-names>JJ</given-names></name><name><surname>van Furth</surname><given-names>R</given-names></name></person-group><article-title>Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy</article-title><source>Infect Immun</source><year>1996</year><volume>64</volume><fpage>4883</fpage><lpage>4890</lpage><?supplied-pmid 8945522?><pub-id pub-id-type="pmid">8945522</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leib</surname><given-names>SL</given-names></name><name><surname>Clements</surname><given-names>JM</given-names></name><name><surname>Lindberg</surname><given-names>RLP</given-names></name><etal/></person-group><article-title>Inhibition of matrix metalloproteinases and tumour necrosis factor &#x003b1; converting enzyme as adjuvant therapy in pneumococcal meningitis</article-title><source>Brain</source><year>2001</year><volume>124</volume><fpage>1734</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1093/brain/124.9.1734</pub-id><?supplied-pmid 11522576?><pub-id pub-id-type="pmid">11522576</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leib</surname><given-names>SL</given-names></name><name><surname>Leppert</surname><given-names>D</given-names></name><name><surname>Clements</surname><given-names>J</given-names></name><name><surname>T&#x000e4;uber</surname><given-names>MG</given-names></name></person-group><article-title>Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis</article-title><source>Infect Immun</source><year>2000</year><volume>68</volume><fpage>615</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.2.615-620.2000</pub-id><pub-id pub-id-type="pmid">10639424</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>GA</given-names></name></person-group><article-title>Matrix metalloproteinases and their multiple roles in neurodegenerative diseases</article-title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(09)70016-X</pub-id><?supplied-pmid 19161911?><pub-id pub-id-type="pmid">19161911</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leppert</surname><given-names>D</given-names></name><name><surname>Lindberg</surname><given-names>RLP</given-names></name><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Leib</surname><given-names>SL</given-names></name></person-group><article-title>Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis</article-title><source>Brain Res Rev</source><year>2001</year><volume>36</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/S0165-0173(01)00101-1</pub-id><?supplied-pmid 11690622?><pub-id pub-id-type="pmid">11690622</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schubert-Unkmeir</surname><given-names>A</given-names></name><name><surname>Konrad</surname><given-names>C</given-names></name><name><surname>Slanina</surname><given-names>H</given-names></name><etal/></person-group><article-title>Neisseria meningitidis induces brain microvascular endothelial cell detachment from the matrix and cleavage of occludin: a role for MMP-8</article-title><source>PLoS Pathog</source><year>2010</year><volume>6</volume><fpage>e1000874</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1000874</pub-id><?supplied-pmid 20442866?><pub-id pub-id-type="pmid">20442866</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meli</surname><given-names>D</given-names></name><name><surname>Loeffler</surname><given-names>J</given-names></name><name><surname>Baumann</surname><given-names>P</given-names></name><etal/></person-group><article-title>In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-&#x003b1; converting enzyme attenuates seizures and injury of the cerebral cortex</article-title><source>J Neuroimmunol</source><year>2004</year><volume>151</volume><fpage>6</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2004.01.026</pub-id><?supplied-pmid 15145598?><pub-id pub-id-type="pmid">15145598</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandler</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>KM</given-names></name><name><surname>Clements</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview</article-title><source>J Neuroimmunol</source><year>1997</year><volume>72</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(96)00179-8</pub-id><pub-id pub-id-type="pmid">9042108</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asahi</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia</article-title><source>J Neurosci</source><year>2001</year><volume>21</volume><fpage>7724</fpage><lpage>7732</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.21-19-07724.2001</pub-id><pub-id pub-id-type="pmid">11567062</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f6;ttcher</surname><given-names>T</given-names></name><name><surname>Spreer</surname><given-names>A</given-names></name><name><surname>Azeh</surname><given-names>I</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-9 deficiency impairs host defense mechanisms against <italic>Streptococcus pneumoniae</italic> in a mouse model of bacterial meningitis</article-title><source>Neurosci Lett</source><year>2003</year><volume>338</volume><fpage>201</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(02)01406-4</pub-id><?supplied-pmid 12581831?><pub-id pub-id-type="pmid">12581831</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><etal/></person-group><article-title>A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>6401</fpage><lpage>6408</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1563-05.2005</pub-id><?supplied-pmid 16000631?><pub-id pub-id-type="pmid">16000631</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Role of matrix metalloproteinase-9 in apoptosis of hippocampal neurons in rats during early brain injury after subarachnoid hemorrhage</article-title><source>Neurol Sci</source><year>2010</year><volume>31</volume><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1007/s10072-009-0192-x</pub-id><?supplied-pmid 20033829?><pub-id pub-id-type="pmid">20033829</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindberg</surname><given-names>RLP</given-names></name><name><surname>Sorsa</surname><given-names>T</given-names></name><name><surname>Tervahartiala</surname><given-names>T</given-names></name><etal/></person-group><article-title>Gelatinase B [matrix metalloproteinase (MMP)-9] and collagenases (MMP-8/-13) are upregulated in cerebrospinal fluid during aseptic and bacterial meningitis in children</article-title><source>Neuropathol Appl Neurobiol</source><year>2006</year><volume>32</volume><fpage>304</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2006.00729.x</pub-id><?supplied-pmid 16640649?><pub-id pub-id-type="pmid">16640649</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>A</given-names></name><name><surname>Lahat</surname><given-names>N</given-names></name><etal/></person-group><article-title>Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis</article-title><source>J Neurol Sci</source><year>2003</year><volume>206</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/S0022-510X(02)00317-9</pub-id><?supplied-pmid 12480084?><pub-id pub-id-type="pmid">12480084</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yushchenko</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>F</given-names></name><name><surname>M&#x000e4;der</surname><given-names>M</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count</article-title><source>J Neuroimmunol</source><year>2000</year><volume>110</volume><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(00)00339-8</pub-id><?supplied-pmid 11024556?><pub-id pub-id-type="pmid">11024556</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>JA</given-names></name><name><surname>Thi Hong Chau</surname><given-names>T</given-names></name><name><surname>Farrar</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>CNS infection, CSF matrix metalloproteinase concentrations, and clinical/laboratory features</article-title><source>Neurology</source><year>2011</year><volume>76</volume><fpage>577</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31820b7600</pub-id><?supplied-pmid 21300974?><pub-id pub-id-type="pmid">21300974</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>H-C</given-names></name><name><surname>Shi</surname><given-names>M-H</given-names></name><name><surname>Lee</surname><given-names>SS-J</given-names></name><etal/></person-group><article-title>Expression of matrix metalloproteinases and their tissue inhibitors in the serum and cerebrospinal fluid of patients with meningitis</article-title><source>Clin Microbiol Infect</source><year>2011</year><volume>17</volume><fpage>780</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2010.03393.x</pub-id><?supplied-pmid 21521415?><pub-id pub-id-type="pmid">21521415</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koopmans</surname><given-names>MM</given-names></name><name><surname>Brouwer</surname><given-names>MC</given-names></name><name><surname>Geldhoff</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid inflammatory markers in patients with <italic>Listeria</italic> monocytogenes meningitis</article-title><source>BBA Clin</source><year>2014</year><volume>1</volume><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/J.BBACLI.2014.06.001</pub-id><?supplied-pmid 25960946?><pub-id pub-id-type="pmid">25960946</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roine</surname><given-names>I</given-names></name><name><surname>Pelkonen</surname><given-names>T</given-names></name><name><surname>Lauhio</surname><given-names>A</given-names></name><etal/></person-group><article-title>Changes in MMP-9 and TIMP-1 concentrations in cerebrospinal fluid after 1 week of treatment of childhood bacterial meningitis</article-title><source>J Clin Microbiol</source><year>2015</year><volume>53</volume><fpage>2340</fpage><lpage>2342</lpage><pub-id pub-id-type="doi">10.1128/JCM.00714-15</pub-id><?supplied-pmid 25903567?><pub-id pub-id-type="pmid">25903567</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandgirard</surname><given-names>D</given-names></name><name><surname>G&#x000e4;umann</surname><given-names>R</given-names></name><name><surname>Coulibaly</surname><given-names>B</given-names></name><etal/></person-group><article-title>The causative pathogen determines the inflammatory profile in cerebrospinal fluid and outcome in patients with bacterial meningitis</article-title><source>Mediat Inflamm</source><year>2013</year><volume>2013</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1155/2013/312476</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majeed</surname><given-names>S</given-names></name><name><surname>Radotra</surname><given-names>BD</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name></person-group><article-title>Adjunctive role of MMP-9 inhibition along with conventional anti-tubercular drugs against experimental tuberculous meningitis</article-title><source>Int J Exp Pathol</source><year>2016</year><volume>97</volume><fpage>230</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1111/iep.12191</pub-id><?supplied-pmid 27385155?><pub-id pub-id-type="pmid">27385155</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KY</given-names></name><name><surname>Kim</surname><given-names>EH</given-names></name><name><surname>Yang</surname><given-names>WS</given-names></name><etal/></person-group><article-title>Persistent increase of matrix metalloproteinases in cerebrospinal fluid of tuberculous meningitis</article-title><source>J Neurol Sci</source><year>2004</year><volume>220</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2004.02.008</pub-id><?supplied-pmid 15140609?><pub-id pub-id-type="pmid">15140609</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majeed</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name></person-group><article-title>Title: role of matrix metalloproteinase-9 in progression of tuberculous meningitis: a pilot study in patients at different stages of the disease</article-title><source>BMC Infect Dis</source><year>2016</year><volume>16</volume><fpage>722</fpage><pub-id pub-id-type="doi">10.1186/s12879-016-1953-9</pub-id><?supplied-pmid 27899068?><pub-id pub-id-type="pmid">27899068</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>JA</given-names></name><name><surname>Tran</surname><given-names>CTH</given-names></name><name><surname>Farrar</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Dexamethasone, cerebrospinal fluid matrix metalloproteinase concentrations and clinical outcomes in tuberculous meningitis</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e7277</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0007277</pub-id><?supplied-pmid 19789647?><pub-id pub-id-type="pmid">19789647</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thwaites</surname><given-names>GE</given-names></name><name><surname>Bang</surname><given-names>ND</given-names></name><name><surname>Dung</surname><given-names>NH</given-names></name><etal/></person-group><article-title>Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>1741</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa040573</pub-id><?supplied-pmid 15496623?><pub-id pub-id-type="pmid">15496623</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spindler</surname><given-names>KR</given-names></name><name><surname>Hsu</surname><given-names>T-H</given-names></name></person-group><article-title>Viral disruption of the blood-brain barrier</article-title><source>Trends Microbiol</source><year>2012</year><volume>20</volume><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2012.03.009</pub-id><?supplied-pmid 22564250?><pub-id pub-id-type="pmid">22564250</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolb</surname><given-names>SA</given-names></name><name><surname>Lahrtz</surname><given-names>F</given-names></name><name><surname>Paul</surname><given-names>R</given-names></name><etal/></person-group><article-title>Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid</article-title><source>J Neuroimmunol</source><year>1998</year><volume>84</volume><fpage>143</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(97)00247-6</pub-id><pub-id pub-id-type="pmid">9628456</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tung</surname><given-names>W-H</given-names></name><name><surname>Tsai</surname><given-names>H-W</given-names></name><name><surname>Lee</surname><given-names>I-T</given-names></name><etal/></person-group><article-title>Japanese encephalitis virus induces matrix metalloproteinase-9 in rat brain astrocytes via NF-&#x003ba;B signalling dependent on MAPKs and reactive oxygen species</article-title><source>Br J Pharmacol</source><year>2010</year><volume>161</volume><fpage>1566</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00982.x</pub-id><?supplied-pmid 20698853?><pub-id pub-id-type="pmid">20698853</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shukla</surname><given-names>V</given-names></name><name><surname>Kumar Shakya</surname><given-names>A</given-names></name><name><surname>Dhole</surname><given-names>TN</given-names></name><name><surname>Misra</surname><given-names>UK</given-names></name></person-group><article-title>Upregulated expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in BALB/c mouse brain challenged with Japanese encephalitis virus</article-title><source>NeuroImmunoModulation</source><year>2012</year><volume>19</volume><fpage>241</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1159/000335182</pub-id><?supplied-pmid 22441541?><pub-id pub-id-type="pmid">22441541</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sellner</surname><given-names>J</given-names></name><name><surname>Simon</surname><given-names>F</given-names></name><name><surname>Meyding-Lamade</surname><given-names>U</given-names></name><name><surname>Leib</surname><given-names>SL</given-names></name></person-group><article-title>Herpes-simplex virus encephalitis is characterized by an early MMP-9 increase and collagen type IV degradation</article-title><source>Brain Res</source><year>2006</year><volume>1125</volume><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.09.093</pub-id><?supplied-pmid 17109833?><pub-id pub-id-type="pmid">17109833</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Gurjav</surname><given-names>U</given-names></name><etal/></person-group><article-title>Reversal of West Nile virus-induced blood&#x02013;brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor</article-title><source>Virology</source><year>2010</year><volume>397</volume><fpage>130</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2009.10.036</pub-id><?supplied-pmid 19922973?><pub-id pub-id-type="pmid">19922973</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Bai</surname><given-names>F</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase 9 facilitates West Nile Virus entry into the brain</article-title><source>J Virol</source><year>2008</year><volume>82</volume><fpage>8978</fpage><lpage>8985</lpage><pub-id pub-id-type="doi">10.1128/JVI.00314-08</pub-id><?supplied-pmid 18632868?><pub-id pub-id-type="pmid">18632868</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eugenin</surname><given-names>EA</given-names></name><name><surname>Osiecki</surname><given-names>K</given-names></name><name><surname>Lopez</surname><given-names>L</given-names></name><etal/></person-group><article-title>CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><fpage>1098</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3863-05.2006</pub-id><?supplied-pmid 16436595?><pub-id pub-id-type="pmid">16436595</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louboutin</surname><given-names>J-P</given-names></name><name><surname>Agrawal</surname><given-names>L</given-names></name><name><surname>Reyes</surname><given-names>BAS</given-names></name><etal/></person-group><article-title>HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress</article-title><source>J Neuropathol Exp Neurol</source><year>2010</year><volume>69</volume><fpage>801</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e3181e8c96f</pub-id><?supplied-pmid 20613638?><pub-id pub-id-type="pmid">20613638</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conant</surname><given-names>K</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name><name><surname>Griffin</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia</article-title><source>Ann Neurol</source><year>1999</year><volume>46</volume><fpage>391</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(199909)46:3&#x0003c;391::AID-ANA15&#x0003e;3.0.CO;2-0</pub-id><pub-id pub-id-type="pmid">10482270</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liuzzi</surname><given-names>GM</given-names></name><name><surname>Mastroianni</surname><given-names>CM</given-names></name><name><surname>Santacroce</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases</article-title><source>J Neurovirol</source><year>2000</year><volume>6</volume><fpage>156</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.3109/13550280009013159</pub-id><pub-id pub-id-type="pmid">10822329</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tirumuru</surname><given-names>N</given-names></name><name><surname>Pretto</surname><given-names>CD</given-names></name><name><surname>Castro Jorge</surname><given-names>LA</given-names></name><name><surname>Spindler</surname><given-names>KR</given-names></name></person-group><article-title>Mouse adenovirus type 1 early region 1A effects on the blood-brain barrier</article-title><source>mSphere</source><year>2016</year><volume>1</volume><fpage>e00079-16</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00079-16</pub-id><?supplied-pmid 27303733?><pub-id pub-id-type="pmid">27303733</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashley</surname><given-names>SL</given-names></name><name><surname>Pretto</surname><given-names>CD</given-names></name><name><surname>Stier</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase activity in infections by an encephalitic virus, mouse adenovirus type 1</article-title><source>J Virol</source><year>2017</year><volume>91</volume><fpage>e01412-16</fpage><pub-id pub-id-type="doi">10.1128/JVI.01412-16</pub-id><?supplied-pmid 28053109?><pub-id pub-id-type="pmid">28053109</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Ashley</surname><given-names>SL</given-names></name><name><surname>Dixon</surname><given-names>SD</given-names></name><name><surname>Spindler</surname><given-names>KR</given-names></name></person-group><article-title>Mouse adenovirus type 1-induced breakdown of the blood-brain barrier</article-title><source>J Virol</source><year>2009</year><volume>83</volume><fpage>9398</fpage><lpage>9410</lpage><pub-id pub-id-type="doi">10.1128/JVI.00954-09</pub-id><?supplied-pmid 19570856?><pub-id pub-id-type="pmid">19570856</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Marten</surname><given-names>NW</given-names></name><name><surname>Bergmann</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Expression of matrix metalloproteinases and their tissue inhibitor during viral encephalitis</article-title><source>J Virol</source><year>2005</year><volume>79</volume><fpage>4764</fpage><lpage>4773</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.8.4764-4773.2005</pub-id><?supplied-pmid 15795262?><pub-id pub-id-type="pmid">15795262</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Stohlman</surname><given-names>SA</given-names></name><name><surname>Atkinson</surname><given-names>R</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase expression correlates with virulence following neurotropic mouse hepatitis virus infection</article-title><source>J Virol</source><year>2002</year><volume>76</volume><fpage>7374</fpage><lpage>7384</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.15.7374-7384.2002</pub-id><pub-id pub-id-type="pmid">12097550</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liechti</surname><given-names>FD</given-names></name><name><surname>Grandgirard</surname><given-names>D</given-names></name><name><surname>Leppert</surname><given-names>D</given-names></name><name><surname>Leib</surname><given-names>SL</given-names></name></person-group><article-title>Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis</article-title><source>Infect Immun</source><year>2014</year><volume>82</volume><fpage>1710</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.1128/IAI.00073-14</pub-id><?supplied-pmid 24491581?><pub-id pub-id-type="pmid">24491581</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liechti</surname><given-names>FD</given-names></name><name><surname>B&#x000e4;chtold</surname><given-names>F</given-names></name><name><surname>Grandgirard</surname><given-names>D</given-names></name><etal/></person-group><article-title>The matrix metalloproteinase inhibitor RS-130830 attenuates brain injury in experimental pneumococcal meningitis</article-title><source>J Neuroinflamm</source><year>2015</year><volume>12</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s12974-015-0257-0</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Grandgirard</surname><given-names>D</given-names></name><name><surname>Wenzel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis</article-title><source>BMC Infect Dis</source><year>2014</year><volume>14</volume><fpage>726</fpage><pub-id pub-id-type="doi">10.1186/s12879-014-0726-6</pub-id><?supplied-pmid 25551808?><pub-id pub-id-type="pmid">25551808</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Echchannaoui</surname><given-names>H</given-names></name><name><surname>Leib</surname><given-names>SL</given-names></name><name><surname>Neumann</surname><given-names>U</given-names></name><name><surname>Landmann</surname><given-names>RM</given-names></name></person-group><article-title>Adjuvant TACE inhibitor treatment improves the outcome of TLR2<sup>&#x02212;<italic>/</italic>&#x02212;</sup>-mice with experimental pneumococcal meningitis</article-title><source>BMC Infect Dis</source><year>2007</year><volume>7</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-7-25</pub-id><?supplied-pmid 17428319?><pub-id pub-id-type="pmid">17428319</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>GA</given-names></name><name><surname>Estrada</surname><given-names>EY</given-names></name><name><surname>Mobashery</surname><given-names>S</given-names></name></person-group><article-title>Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood&#x02013;brain barrier opening in rodents: differences in response based on strains and solvents</article-title><source>Brain Res</source><year>2007</year><volume>1133</volume><fpage>186</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.11.041</pub-id><?supplied-pmid 17184743?><pub-id pub-id-type="pmid">17184743</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>R</given-names></name><name><surname>Lorenzl</surname><given-names>S</given-names></name><name><surname>Koedel</surname><given-names>U</given-names></name><etal/></person-group><article-title>Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis</article-title><source>Ann Neurol</source><year>1998</year><volume>44</volume><fpage>592</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1002/ana.410440404</pub-id><?supplied-pmid 9778257?><pub-id pub-id-type="pmid">9778257</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meli</surname><given-names>DN</given-names></name><name><surname>Coimbra</surname><given-names>RS</given-names></name><name><surname>Erhart</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis</article-title><source>Infect Immun</source><year>2006</year><volume>74</volume><fpage>3890</fpage><lpage>3896</lpage><pub-id pub-id-type="doi">10.1128/IAI.01949-05</pub-id><?supplied-pmid 16790761?><pub-id pub-id-type="pmid">16790761</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muri</surname><given-names>L</given-names></name><name><surname>Grandgirard</surname><given-names>D</given-names></name><name><surname>Buri</surname><given-names>M</given-names></name><etal/></person-group><article-title>Combined effect of non-bacteriolytic antibiotic and inhibition of matrix metalloproteinases prevents brain injury and preserves learning, memory and hearing function in experimental paediatric pneumococcal meningitis</article-title><source>J Neuroinflamm</source><year>2018</year><volume>15</volume><fpage>233</fpage><pub-id pub-id-type="doi">10.1186/s12974-018-1272-8</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandgirard</surname><given-names>D</given-names></name><name><surname>Steiner</surname><given-names>O</given-names></name><name><surname>T&#x000e4;uber</surname><given-names>MG</given-names></name><name><surname>Leib</surname><given-names>SL</given-names></name></person-group><article-title>An infant mouse model of brain damage in pneumococcal meningitis</article-title><source>Acta Neuropathol</source><year>2007</year><volume>114</volume><fpage>609</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1007/s00401-007-0304-8</pub-id><?supplied-pmid 17938941?><pub-id pub-id-type="pmid">17938941</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bifrare</surname><given-names>Y-D</given-names></name><name><surname>Gianinazzi</surname><given-names>C</given-names></name><name><surname>Imboden</surname><given-names>H</given-names></name><etal/></person-group><article-title>Bacterial meningitis causes two distinct forms of cellular damage in the hippocampal dentate gyrus in infant rats</article-title><source>Hippocampus</source><year>2003</year><volume>13</volume><fpage>481</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1002/hipo.10142</pub-id><?supplied-pmid 12836917?><pub-id pub-id-type="pmid">12836917</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name></person-group><article-title>Efficacy of GM6001 as an adjuvant to ceftriaxone in a neonatal rat model of <italic>Streptococcus pneumoniae</italic> meningitis</article-title><source>Acta Neurobiol Exp (Wars)</source><year>2014</year><volume>74</volume><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">25576979</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barichello</surname><given-names>T</given-names></name><name><surname>Generoso</surname><given-names>JS</given-names></name><name><surname>Michelon</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats</article-title><source>Exp Biol Med (Maywood)</source><year>2014</year><volume>239</volume><fpage>225</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1177/1535370213508354</pub-id><pub-id pub-id-type="pmid">24419461</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerber</surname><given-names>J</given-names></name><name><surname>B&#x000f6;ttcher</surname><given-names>T</given-names></name><name><surname>Hahn</surname><given-names>M</given-names></name><etal/></person-group><article-title>Increased mortality and spatial memory deficits in TNF-&#x003b1;-deficient mice in ceftriaxone-treated experimental pneumococcal meningitis</article-title><source>Neurobiol Dis</source><year>2004</year><volume>16</volume><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/J.NBD.2004.01.013</pub-id><?supplied-pmid 15207270?><pub-id pub-id-type="pmid">15207270</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Baranzini</surname><given-names>SE</given-names></name><name><surname>Geurts</surname><given-names>J</given-names></name><etal/></person-group><article-title>Multiple sclerosis</article-title><source>Lancet</source><year>2018</year><volume>391</volume><fpage>1622</fpage><lpage>1636</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)30481-1</pub-id><?supplied-pmid 29576504?><pub-id pub-id-type="pmid">29576504</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobson</surname><given-names>R</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name></person-group><article-title>Multiple sclerosis&#x02014;a review</article-title><source>Eur J Neurol</source><year>2018</year><pub-id pub-id-type="doi">10.1111/ene.13819</pub-id><?supplied-pmid 30300457?><pub-id pub-id-type="pmid">30300457</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutzelnigg</surname><given-names>A</given-names></name><name><surname>Lucchinetti</surname><given-names>CF</given-names></name><name><surname>Stadelmann</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cortical demyelination and diffuse white matter injury in multiple sclerosis</article-title><source>Brain</source><year>2005</year><volume>128</volume><fpage>2705</fpage><lpage>2712</lpage><pub-id pub-id-type="doi">10.1093/brain/awh641</pub-id><?supplied-pmid 16230320?><pub-id pub-id-type="pmid">16230320</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapp</surname><given-names>BD</given-names></name><name><surname>Vignos</surname><given-names>M</given-names></name><name><surname>Dudman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study</article-title><source>Lancet Neurol</source><year>2018</year><volume>17</volume><fpage>870</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(18)30245-X</pub-id><?supplied-pmid 30143361?><pub-id pub-id-type="pmid">30143361</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenfield</surname><given-names>AL</given-names></name><name><surname>Hauser</surname><given-names>SL</given-names></name></person-group><article-title>B-cell therapy for multiple sclerosis: entering an era</article-title><source>Ann Neurol</source><year>2018</year><volume>83</volume><fpage>13</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1002/ana.25119</pub-id><?supplied-pmid 29244240?><pub-id pub-id-type="pmid">29244240</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waubant</surname><given-names>E</given-names></name><name><surname>Goodkin</surname><given-names>DE</given-names></name><name><surname>Gee</surname><given-names>L</given-names></name><etal/></person-group><article-title>Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis</article-title><source>Neurology</source><year>1999</year><volume>53</volume><fpage>1397</fpage><lpage>1401</lpage><pub-id pub-id-type="doi">10.1212/WNL.53.7.1397</pub-id><pub-id pub-id-type="pmid">10534241</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anthony</surname><given-names>DC</given-names></name><name><surname>Ferguson</surname><given-names>B</given-names></name><name><surname>Matyzak</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke</article-title><source>Neuropathol Appl Neurobiol</source><year>1997</year><volume>23</volume><fpage>406</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.1997.tb01315.x</pub-id><pub-id pub-id-type="pmid">9364466</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cossins</surname><given-names>JA</given-names></name><name><surname>Clements</surname><given-names>JM</given-names></name><name><surname>Ford</surname><given-names>J</given-names></name><etal/></person-group><article-title>Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions</article-title><source>Acta Neuropathol</source><year>1997</year><volume>94</volume><fpage>590</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1007/s004010050754</pub-id><pub-id pub-id-type="pmid">9444361</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>A</given-names></name><name><surname>Sobel</surname><given-names>RA</given-names></name></person-group><article-title>Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions</article-title><source>J Neuropathol Exp Neurol</source><year>1996</year><volume>55</volume><fpage>300</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1097/00005072-199603000-00005</pub-id><pub-id pub-id-type="pmid">8786388</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindberg</surname><given-names>RL</given-names></name><name><surname>De Groot</surname><given-names>CJ</given-names></name><name><surname>Montagne</surname><given-names>L</given-names></name><etal/></person-group><article-title>The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis</article-title><source>Brain</source><year>2001</year><volume>124</volume><fpage>1743</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1093/brain/124.9.1743</pub-id><pub-id pub-id-type="pmid">11522577</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieseier</surname><given-names>BC</given-names></name><name><surname>Kiefer</surname><given-names>R</given-names></name><name><surname>Clements</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis</article-title><source>Brain</source><year>1998</year><volume>121</volume><issue>Pt 1</issue><fpage>159</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1093/brain/121.1.159</pub-id><pub-id pub-id-type="pmid">9549496</pub-id></element-citation></ref><ref id="CR191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Masure</surname><given-names>S</given-names></name><name><surname>Hurtenbach</surname><given-names>U</given-names></name><etal/></person-group><article-title>Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions</article-title><source>J Clin Invest</source><year>1999</year><volume>104</volume><fpage>1507</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1172/JCI6886</pub-id><?supplied-pmid 10587514?><pub-id pub-id-type="pmid">10587514</pub-id></element-citation></ref><ref id="CR192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anthony</surname><given-names>DC</given-names></name><name><surname>Miller</surname><given-names>KM</given-names></name><name><surname>Fearn</surname><given-names>S</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS</article-title><source>J Neuroimmunol</source><year>1998</year><volume>87</volume><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(98)00046-0</pub-id><pub-id pub-id-type="pmid">9670846</pub-id></element-citation></ref><ref id="CR193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>TA</given-names></name><name><surname>Woolley</surname><given-names>ST</given-names></name><name><surname>Hughes</surname><given-names>PM</given-names></name><etal/></person-group><article-title>T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases</article-title><source>Brain</source><year>2001</year><volume>124</volume><fpage>2203</fpage><lpage>2214</lpage><pub-id pub-id-type="doi">10.1093/brain/124.11.2203</pub-id><?supplied-pmid 11673322?><pub-id pub-id-type="pmid">11673322</pub-id></element-citation></ref><ref id="CR194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sellebjerg</surname><given-names>F</given-names></name><name><surname>B&#x000f6;rnsen</surname><given-names>L</given-names></name><name><surname>Ammitzb&#x000f8;ll</surname><given-names>C</given-names></name><etal/></person-group><article-title>Defining active progressive multiple sclerosis</article-title><source>Mult Scler J</source><year>2017</year><volume>23</volume><fpage>1727</fpage><lpage>1735</lpage><pub-id pub-id-type="doi">10.1177/1352458517726592</pub-id></element-citation></ref><ref id="CR195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leppert</surname><given-names>D</given-names></name><name><surname>Ford</surname><given-names>J</given-names></name><name><surname>Stabler</surname><given-names>G</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis</article-title><source>Brain</source><year>1998</year><volume>121</volume><issue>Pt 12</issue><fpage>2327</fpage><lpage>2334</lpage><pub-id pub-id-type="doi">10.1093/brain/121.12.2327</pub-id><pub-id pub-id-type="pmid">9874483</pub-id></element-citation></ref><ref id="CR196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gijbels</surname><given-names>K</given-names></name><name><surname>Masure</surname><given-names>S</given-names></name><name><surname>Carton</surname><given-names>H</given-names></name><name><surname>Opdenakker</surname><given-names>G</given-names></name></person-group><article-title>Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders</article-title><source>J Neuroimmunol</source><year>1992</year><volume>41</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/0165-5728(92)90192-N</pub-id><pub-id pub-id-type="pmid">1334098</pub-id></element-citation></ref><ref id="CR197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MA</given-names></name><name><surname>Palace</surname><given-names>J</given-names></name><name><surname>Stabler</surname><given-names>G</given-names></name><etal/></person-group><article-title>Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study</article-title><source>Brain</source><year>1999</year><volume>122</volume><issue>Pt 2</issue><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1093/brain/122.2.191</pub-id><pub-id pub-id-type="pmid">10071048</pub-id></element-citation></ref><ref id="CR198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waubant</surname><given-names>E</given-names></name><name><surname>Goodkin</surname><given-names>D</given-names></name><name><surname>Bostrom</surname><given-names>A</given-names></name><etal/></person-group><article-title>IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS</article-title><source>Neurology</source><year>2003</year><volume>60</volume><fpage>52</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1212/WNL.60.1.52</pub-id><pub-id pub-id-type="pmid">12525717</pub-id></element-citation></ref><ref id="CR199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>GA</given-names></name><name><surname>Dencoff</surname><given-names>JE</given-names></name><name><surname>Correa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury</article-title><source>Neurology</source><year>1996</year><volume>46</volume><fpage>1626</fpage><lpage>1632</lpage><pub-id pub-id-type="doi">10.1212/WNL.46.6.1626</pub-id><pub-id pub-id-type="pmid">8649561</pub-id></element-citation></ref><ref id="CR200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilli</surname><given-names>F</given-names></name><name><surname>Bertolotto</surname><given-names>A</given-names></name><name><surname>Sala</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neutralizing antibodies against IFN- in multiple sclerosis: antagonization of IFN- mediated suppression of MMPs</article-title><source>Brain</source><year>2004</year><volume>127</volume><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1093/brain/awh028</pub-id><?supplied-pmid 14607790?><pub-id pub-id-type="pmid">14607790</pub-id></element-citation></ref><ref id="CR201"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar-Or</surname><given-names>A</given-names></name><name><surname>Nuttall</surname><given-names>RK</given-names></name><name><surname>Duddy</surname><given-names>M</given-names></name><etal/></person-group><article-title>Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis</article-title><source>Brain</source><year>2003</year><volume>126</volume><fpage>2738</fpage><lpage>2749</lpage><pub-id pub-id-type="doi">10.1093/brain/awg285</pub-id><?supplied-pmid 14506071?><pub-id pub-id-type="pmid">14506071</pub-id></element-citation></ref><ref id="CR202"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouwenhoven</surname><given-names>M</given-names></name><name><surname>&#x000d6;zenci</surname><given-names>V</given-names></name><name><surname>Gomes</surname><given-names>A</given-names></name><etal/></person-group><article-title>Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes</article-title><source>J Autoimmun</source><year>2001</year><volume>16</volume><fpage>463</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1006/jaut.2001.0505</pub-id><?supplied-pmid 11437495?><pub-id pub-id-type="pmid">11437495</pub-id></element-citation></ref><ref id="CR203"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>LY</given-names></name><name><surname>Larsen</surname><given-names>PH</given-names></name><name><surname>Krekoski</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes</article-title><source>J Neurosci</source><year>1999</year><volume>19</volume><fpage>8464</fpage><lpage>8475</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.19-19-08464.1999</pub-id><pub-id pub-id-type="pmid">10493747</pub-id></element-citation></ref><ref id="CR204"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Gorter</surname><given-names>RP</given-names></name><name><surname>de Jonge</surname><given-names>JC</given-names></name><etal/></person-group><article-title>MMP7 cleaves remyelination-impairing fibronectin aggregates and its expression is reduced in chronic multiple sclerosis lesions</article-title><source>Glia</source><year>2018</year><volume>66</volume><fpage>1625</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1002/glia.23328</pub-id><?supplied-pmid 29600597?><pub-id pub-id-type="pmid">29600597</pub-id></element-citation></ref><ref id="CR205"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dear</surname><given-names>ML</given-names></name><name><surname>Shilts</surname><given-names>J</given-names></name><name><surname>Broadie</surname><given-names>K</given-names></name></person-group><article-title>Neuronal activity drives FMRP- and HSPG-dependent matrix metalloproteinase function required for rapid synaptogenesis</article-title><source>Sci Signal</source><year>2017</year><volume>10</volume><fpage>eaan3181</fpage><pub-id pub-id-type="doi">10.1126/scisignal.aan3181</pub-id><?supplied-pmid 29114039?><pub-id pub-id-type="pmid">29114039</pub-id></element-citation></ref><ref id="CR206"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinhard</surname><given-names>SM</given-names></name><name><surname>Razak</surname><given-names>K</given-names></name><name><surname>Ethell</surname><given-names>IM</given-names></name></person-group><article-title>A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders</article-title><source>Front Cell Neurosci</source><year>2015</year><volume>9</volume><fpage>280</fpage><pub-id pub-id-type="doi">10.3389/fncel.2015.00280</pub-id><?supplied-pmid 26283917?><pub-id pub-id-type="pmid">26283917</pub-id></element-citation></ref><ref id="CR207"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romme Christensen</surname><given-names>J</given-names></name><name><surname>Ratzer</surname><given-names>R</given-names></name><name><surname>Bornsen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial</article-title><source>Neurology</source><year>2014</year><volume>82</volume><fpage>1499</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000361</pub-id><?supplied-pmid 24682973?><pub-id pub-id-type="pmid">24682973</pub-id></element-citation></ref><ref id="CR208"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St&#x000fc;ve</surname><given-names>O</given-names></name><name><surname>Dooley</surname><given-names>NP</given-names></name><name><surname>Uhm</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Interferon &#x003b2;-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9</article-title><source>Ann Neurol</source><year>1996</year><volume>40</volume><fpage>853</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1002/ana.410400607</pub-id><?supplied-pmid 9007090?><pub-id pub-id-type="pmid">9007090</pub-id></element-citation></ref><ref id="CR209"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leppert</surname><given-names>D</given-names></name><name><surname>Waubant</surname><given-names>E</given-names></name><name><surname>B&#x000fc;rk</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis</article-title><source>Ann Neurol</source><year>1996</year><volume>40</volume><fpage>846</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1002/ana.410400606</pub-id><?supplied-pmid 9007089?><pub-id pub-id-type="pmid">9007089</pub-id></element-citation></ref><ref id="CR210"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clements</surname><given-names>JM</given-names></name><name><surname>Cossins</surname><given-names>JA</given-names></name><name><surname>Wells</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor</article-title><source>J Neuroimmunol</source><year>1997</year><volume>74</volume><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(96)00210-X</pub-id><pub-id pub-id-type="pmid">9119983</pub-id></element-citation></ref><ref id="CR211"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewson</surname><given-names>AK</given-names></name><name><surname>Smith</surname><given-names>T</given-names></name><name><surname>Leonard</surname><given-names>JP</given-names></name><name><surname>Cuzner</surname><given-names>ML</given-names></name></person-group><article-title>Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790</article-title><source>Inflamm Res</source><year>1995</year><volume>44</volume><fpage>345</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1007/BF01796266</pub-id><pub-id pub-id-type="pmid">8581522</pub-id></element-citation></ref><ref id="CR212"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gijbels</surname><given-names>K</given-names></name><name><surname>Galardy</surname><given-names>RE</given-names></name><name><surname>Steinman</surname><given-names>L</given-names></name></person-group><article-title>Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases</article-title><source>J Clin Invest</source><year>1994</year><volume>94</volume><fpage>2177</fpage><lpage>2182</lpage><pub-id pub-id-type="doi">10.1172/JCI117578</pub-id><?supplied-pmid 7989572?><pub-id pub-id-type="pmid">7989572</pub-id></element-citation></ref><ref id="CR213"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leppert</surname><given-names>D</given-names></name><name><surname>Waubant</surname><given-names>E</given-names></name><name><surname>Galardy</surname><given-names>R</given-names></name><etal/></person-group><article-title>T cell gelatinases mediate basement membrane transmigration in vitro</article-title><source>J Immunol</source><year>1995</year><volume>154</volume><fpage>4379</fpage><lpage>4389</lpage><?supplied-pmid 7722295?><pub-id pub-id-type="pmid">7722295</pub-id></element-citation></ref><ref id="CR214"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keystone</surname><given-names>E</given-names></name></person-group><article-title>Treatments no longer in development for rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2002</year><volume>61</volume><issue>Suppl 2</issue><fpage>ii43</fpage><lpage>ii45</lpage><pub-id pub-id-type="doi">10.1136/ARD.61.SUPPL_2.II43</pub-id><?supplied-pmid 12379620?><pub-id pub-id-type="pmid">12379620</pub-id></element-citation></ref><ref id="CR215"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metz</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Traboulsee</surname><given-names>A</given-names></name><etal/></person-group><article-title>Glatiramer acetate in combination with minocycline in patients with relapsing&#x02014;remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial</article-title><source>Mult Scler J</source><year>2009</year><volume>15</volume><fpage>1183</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1177/1352458509106779</pub-id></element-citation></ref><ref id="CR216"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metz</surname><given-names>LM</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yeung</surname><given-names>M</given-names></name><etal/></person-group><article-title>Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis</article-title><source>Ann Neurol</source><year>2004</year><volume>55</volume><fpage>756</fpage><pub-id pub-id-type="doi">10.1002/ana.20111</pub-id><?supplied-pmid 15122721?><pub-id pub-id-type="pmid">15122721</pub-id></element-citation></ref><ref id="CR217"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metz</surname><given-names>LM</given-names></name><name><surname>Li</surname><given-names>DKB</given-names></name><name><surname>Traboulsee</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Trial of minocycline in a clinically isolated syndrome of multiple sclerosis</article-title><source>N Engl J Med</source><year>2017</year><volume>376</volume><fpage>2122</fpage><lpage>2133</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1608889</pub-id><?supplied-pmid 28564557?><pub-id pub-id-type="pmid">28564557</pub-id></element-citation></ref><ref id="CR218"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>JN</given-names></name><name><surname>Kaushik</surname><given-names>DK</given-names></name><name><surname>Mishra</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Impact of minocycline on extracellular matrix metalloproteinase inducer, a factor implicated in multiple sclerosis immunopathogenesis</article-title><source>J Immunol</source><year>2016</year><volume>197</volume><fpage>3850</fpage><lpage>3860</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1600436</pub-id><?supplied-pmid 27733550?><pub-id pub-id-type="pmid">27733550</pub-id></element-citation></ref><ref id="CR219"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemmings</surname><given-names>FJ</given-names></name><name><surname>Farhan</surname><given-names>M</given-names></name><name><surname>Rowland</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis</article-title><source>Rheumatology (Oxford)</source><year>2001</year><volume>40</volume><fpage>537</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/40.5.537</pub-id><pub-id pub-id-type="pmid">11371662</pub-id></element-citation></ref><ref id="CR220"><label>220.</label><mixed-citation publication-type="other">European Medicines Agency (2015) Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. Committee for medicinal products for human use (CHMP). EMA/CHMP/771815/2011, Rev 2. <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500185161.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500185161.pdf</ext-link>. Accessed 4 June 2019</mixed-citation></ref></ref-list></back></article>